{"rows":[{"id":24,"title":"Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.","normalized_title":"psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex","authors":"Du Y, Zhao X, Yao Y, Li Y, Wang G, Zhang L.","abstract":"BackgroundPosttraumatic stress disorder (PTSD) and major depressive disorder are often comorbid in humans. Psilocybin reportedly has beneficial therapeutic effects on depression, possibly by promoting neuroplasticity. PTSD is associated with the dysregulation of neuroplasticity in the hippocampus and medial prefrontal cortex (mPFC). We hypothesized that psilocybin might reduce fear memory by promoting neuroplasticity in the hippocampus and mPFC.AimsWe investigated the effects of psilocybin on fear memory and explored its underlying mechanisms. We generated a mouse model of PTSD via auditory-cued fear conditioning and treated the mice with either vehicle or psilocybin (2.5 mg/kg, intraperitoneal) on day 0. Fear memory was assessed by the percentage of freezing time in response to conditioned stimuli. Fear memory tests were conducted on days 1, 6, and 7, after which the mice were sacrificed. To investigate the role of neuroplasticity in mediating the effects of psilocybin on fear memory, we assessed structural neuroplasticity and neuroplasticity-associated marker protein levels in the hippocampus and mPFC 7 days after a single dose of psilocybin.ResultsPsilocybin reduced the cue-induced fear response on days 1, 6, and 7. Psilocybin ameliorated the fear conditioning-induced decreases in neuroplasticity in the hippocampus and mPFC. Through Golgi-Cox staining, Western blotting, and immunofluorescence staining, we found that psilocybin increased dendritic branches and spine density, upregulated GluR1 and synapsin-1, enhanced brain-derived neurotrophic factor and mammalian target of rapamycin signaling, and promoted neurogenesis.ConclusionsA single dose of psilocybin reduces both the rapid and sustained fear memory in mice, at least in part by restoring neuroplasticity in the hippocampus and mPFC. These findings indicate that psilocybin has significant potential for use in the treatment of PTSD and other mental disorders characterized by fear memory.","journal":"Journal of Psychopharmacology","publication_date":"2026-06-27","publication_year":2026,"doi":"10.1177/02698811261453819","pubmed_id":"42365496","source_url":"https://doi.org/10.1177/02698811261453819","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-05 01:20:22","raw_json":"{\"europe_pmc_id\":\"42365496\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166436963\",\"openalex_url\":\"https://openalex.org/W7166436963\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W170792860\",\"https://openalex.org/W1980452424\",\"https://openalex.org/W1994547251\",\"https://openalex.org/W2036499082\",\"https://openalex.org/W2051271111\",\"https://openalex.org/W2084108505\",\"https://openalex.org/W2112188963\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2592144218\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2901904956\",\"https://openalex.org/W2927237494\",\"https://openalex.org/W2936046802\",\"https://openalex.org/W2963792090\",\"https://openalex.org/W2992679405\",\"https://openalex.org/W2997242667\",\"https://openalex.org/W3003581149\",\"https://openalex.org/W3011668650\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3100215548\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3112503127\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3126370177\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3157927787\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3165027302\",\"https://openalex.org/W3169261903\",\"https://openalex.org/W3178121559\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3210509042\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4231265947\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4308146113\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4318755662\",\"https://openalex.org/W4362457938\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4401212791\"],\"authorships\":[{\"id\":\"https://openalex.org/A5134867509\",\"display_name\":\"Y J Du\",\"orcid\":null},{\"id\":\"https://openalex.org/A5103220890\",\"display_name\":\"Xinyi Zhao\",\"orcid\":\"https://orcid.org/0009-0007-6483-6148\"},{\"id\":\"https://openalex.org/A5127702000\",\"display_name\":\"Yishan Yao\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139523749\",\"display_name\":\"Yunfeng Li\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088725738\",\"display_name\":\"Guyan Wang\",\"orcid\":\"https://orcid.org/0000-0003-3098-5472\"},{\"id\":\"https://openalex.org/A5101545617\",\"display_name\":\"Liming Zhang\",\"orcid\":\"https://orcid.org/0000-0002-9071-8985\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811261453819\",\"is_oa\":false}}}","topic_tags":"Depression,PTSD,Neuroplasticity,Neurogenesis,Mechanism of Action,Biomarkers,Animal Study","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7166436963"},{"id":34,"title":"Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test","normalized_title":"blocking 5 ht2b receptors abolishes psilocybin s efficacy in the rat forced swim test","authors":"Lenka Seillier, Alexandre Seillier, Morgan A. Zvolska, Romana Šlamberová","abstract":"BACKGROUND: Major depressive disorder is one of the most debilitating psychiatric disorders worldwide. First-line treatments such as selective serotonin reuptake inhibitors have significant limitations, including delayed onset of therapeutic effects and treatment resistance in about 30% of patients. Increasing evidence suggests that acute administration of serotonergic psychedelics, such as psilocybin, produces rapid and long-lasting antidepressant effects, including in treatment-resistant patients. However, it remains unknown which specific 5-HT receptor subtype mediates psilocybin's antidepressant activity. METHODS: We examined in Wistar rats whether pretreatment with the 5-HT2B receptor (5-HT2BR) antagonist RS-127445 (0.32, 1.0, or 3.2 mg/kg) blocked the rapid (day 1) and sustained (day 21) behavioral effects of a single psilocybin administration (0.32 mg/kg) in the forced swim test (FST), a test with predictive validity for antidepressant efficacy. We also measured the impact of RS-127445 on psilocybin-induced head-twitch response (HTR), a behavioral proxy in rodents for psychedelic properties. RESULTS: Our data showed that psilocybin produced both a rapid and sustained decrease in immobility and an increase in climbing behavior in the FST and significantly increased HTR counts. Although RS-127445 did not affect HTR counts at any tested dose, it dose-dependently reversed both the rapid and sustained psilocybin-induced reductions in immobility and increases in climbing behavior. CONCLUSION: These findings indicate that 5-HT2BRs are required for psilocybin's behavioral effects in the FST, but are not required for its HTR. The results add to evidence that psilocybin's predictive validity in the FST can be dissociated from its 5-HT2A-mediated psychedelic effects.","journal":"Journal of Psychopharmacology","publication_date":"2026-06-22","publication_year":2026,"doi":"10.1177/02698811261458349","pubmed_id":"42334341","source_url":"https://doi.org/10.1177/02698811261458349","keywords":"Behavioural despair test, Serotonergic, Antidepressant, Psilocybin, Pharmacology, Antagonist, Tricyclic antidepressant, Serotonin, Psychology, Reuptake inhibitor, Imipramine, Receptor antagonist, Receptor, 5-HT receptor, Internal medicine, Major depressive disorder, Serotonin reuptake inhibitor, Agonist, Endocrinology, Medicine, Anxiogenic, Pindolol, 5-HT1A receptor, Reuptake, Hallucinogen, Mechanism of action, Neurotransmitter, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Neurotransmitter Receptor Influence on Behavior","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-04 07:00:31","raw_json":"{\"openalex_id\":\"https://openalex.org/W7165643590\",\"openalex_url\":\"https://openalex.org/W7165643590\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1961364466\",\"https://openalex.org/W1974074998\",\"https://openalex.org/W1989757811\",\"https://openalex.org/W2007107398\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2012975576\",\"https://openalex.org/W2013598219\",\"https://openalex.org/W2031733304\",\"https://openalex.org/W2047129003\",\"https://openalex.org/W2054695075\",\"https://openalex.org/W2067481209\",\"https://openalex.org/W2089299823\",\"https://openalex.org/W2091064555\",\"https://openalex.org/W2091363925\",\"https://openalex.org/W2126685404\",\"https://openalex.org/W2134518716\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2166952073\",\"https://openalex.org/W2170915041\",\"https://openalex.org/W2173531201\",\"https://openalex.org/W2287930331\",\"https://openalex.org/W2319365136\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2412428225\",\"https://openalex.org/W2511250611\",\"https://openalex.org/W2564232286\",\"https://openalex.org/W2590821743\",\"https://openalex.org/W2596798372\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2999364864\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3042758594\",\"https://openalex.org/W3087095811\",\"https://openalex.org/W3093375227\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3127186731\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W3216485471\",\"https://openalex.org/W4206134470\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4211263234\",\"https://openalex.org/W4293729162\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309269582\",\"https://openalex.org/W4315620747\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4353017554\",\"https://openalex.org/W4385628167\",\"https://openalex.org/W4386504040\",\"https://openalex.org/W4390755783\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4396229906\",\"https://openalex.org/W4400335852\",\"https://openalex.org/W4402327722\",\"https://openalex.org/W4409449430\",\"https://openalex.org/W4410735628\",\"https://openalex.org/W4410737616\",\"https://openalex.org/W4411302754\",\"https://openalex.org/W4415713367\",\"https://openalex.org/W7118172518\",\"https://openalex.org/W7152959768\"],\"authorships\":[{\"id\":\"https://openalex.org/A5067927693\",\"display_name\":\"Lenka Seillier\",\"orcid\":\"https://orcid.org/0000-0002-1041-2290\"},{\"id\":\"https://openalex.org/A5002414770\",\"display_name\":\"Alexandre Seillier\",\"orcid\":\"https://orcid.org/0000-0003-1859-2561\"},{\"id\":\"https://openalex.org/A5139127821\",\"display_name\":\"Morgan A. Zvolska\",\"orcid\":\"https://orcid.org/0009-0002-7335-8022\"},{\"id\":\"https://openalex.org/A5081286729\",\"display_name\":\"Romana Šlamberová\",\"orcid\":\"https://orcid.org/0000-0002-9981-3911\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811261458349\",\"is_oa\":false}}","topic_tags":"Depression,Pharmacology,Mechanism of Action,Receptor Pharmacology,Animal Study,Toxicity","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7165643590"},{"id":92,"title":"Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache","normalized_title":"effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache","authors":"Kristoffer Brendstrup-Brix, Brice Ozenne, Patrick M. Fisher, Dea S. Stenbæk, Anja S. Petersen, Sophia Armand, Drummond E-Wen. McCulloch, Maja Rou Marstrand-Joergensen, Sara M. Ulv Larsen, Annette Johansen, R O B V Jensen, Gitte M. Knudsen, M.K. Madsen","abstract":"BACKGROUND: Patients with chronic cluster headache (CCH) suffer from poor sleep, which may impact their brain microstructure and parenchymal clearance of waste products. Psilocybin has shown promise for the treatment of CCH and has been linked to increased neuroplasticity with possible influences on brain microstructure. AIMS: To investigate the effects of psilocybin on sleep, brain water diffusivity, and microstructure in CCH. METHODS: Eleven CCH patients underwent diffusion-weighted MRI and subjective sleep quality assessment with the Pittsburgh Sleep Quality Index (PSQI) before and 1 week after three psilocybin administrations (0.14 mg/kg) spaced 1 week apart. Measures taken prior to intervention were also compared to 24 healthy controls, and subjective sleep quality was related to brain microstructure and diffusivity across groups. RESULTS: = 0.015). When analyzing brain microstructure and water diffusivity in conjunction, we found differences between CCH patients and controls, which were primarily driven by differences in grey matter. On average, psilocybin intervention in CCH patients was not associated with statistically significant changes in brain microstructure or water diffusivity. However, most patients exhibited lower white matter diffusivity and neurite volume after intervention. Subjective sleep quality showed borderline significant correlations of moderate effect size with brain microstructure and water diffusivity. CONCLUSION: Subjective sleep quality improved in CCH patients after psilocybin and showed some evidence of an association with measures of brain microstructure and water diffusivity. CLINICALTRIALS: gov identifiers:Prophylactic Effects of Psilocybin on Chronic Cluster Headache (EPOCH; NCT04280055) and The Neurobiological Effect of 5-HT2AR Modulation (NeuroPharm2; NCT03289949).","journal":"Journal of Psychopharmacology","publication_date":"2026-05-28","publication_year":2026,"doi":"10.1177/02698811261449380","pubmed_id":"42212900","source_url":"https://doi.org/10.1177/02698811261449380","keywords":"Pittsburgh Sleep Quality Index, Psilocybin, Grey matter, Medicine, Anesthesia, Psychology, White matter, Sleep (system call), Internal medicine, Sleep quality, Crossover study, Cluster headache, Sleep disorder, Quality of life (healthcare), Psychedelics and Drug Studies, Migraine and Headache Studies, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-04 07:00:31","raw_json":"{\"openalex_id\":\"https://openalex.org/W7162798090\",\"openalex_url\":\"https://openalex.org/W7162798090\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1597940528\",\"https://openalex.org/W1729779209\",\"https://openalex.org/W1974298244\",\"https://openalex.org/W1984453610\",\"https://openalex.org/W1986545425\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2003397372\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2102033847\",\"https://openalex.org/W2113619522\",\"https://openalex.org/W2120414185\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2127309075\",\"https://openalex.org/W2136145485\",\"https://openalex.org/W2150280237\",\"https://openalex.org/W2151487996\",\"https://openalex.org/W2167183660\",\"https://openalex.org/W2167399182\",\"https://openalex.org/W2192859497\",\"https://openalex.org/W2286648545\",\"https://openalex.org/W2413955537\",\"https://openalex.org/W2583421592\",\"https://openalex.org/W2768876632\",\"https://openalex.org/W2776811182\",\"https://openalex.org/W2792306715\",\"https://openalex.org/W2801085490\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2886135972\",\"https://openalex.org/W2896007571\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2947426935\",\"https://openalex.org/W2970898057\",\"https://openalex.org/W2977883299\",\"https://openalex.org/W3008898407\",\"https://openalex.org/W3015902292\",\"https://openalex.org/W3104356633\",\"https://openalex.org/W3107150606\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3110820786\",\"https://openalex.org/W3125378830\",\"https://openalex.org/W3145545686\",\"https://openalex.org/W3174100758\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3186659958\",\"https://openalex.org/W3210578847\",\"https://openalex.org/W4210386419\",\"https://openalex.org/W4211228087\",\"https://openalex.org/W4211245039\",\"https://openalex.org/W4212825543\",\"https://openalex.org/W4214823203\",\"https://openalex.org/W4220753844\",\"https://openalex.org/W4220805356\",\"https://openalex.org/W4223896486\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4300960088\",\"https://openalex.org/W4302007737\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309832620\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4361304609\",\"https://openalex.org/W4385987345\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4391036082\",\"https://openalex.org/W4391898793\",\"https://openalex.org/W4394808303\",\"https://openalex.org/W4395691328\",\"https://openalex.org/W4397032013\",\"https://openalex.org/W4400317821\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4403392138\",\"https://openalex.org/W4404321372\",\"https://openalex.org/W4409286565\"],\"authorships\":[{\"id\":\"https://openalex.org/A5054721141\",\"display_name\":\"Kristoffer Brendstrup-Brix\",\"orcid\":\"https://orcid.org/0009-0006-8683-4277\"},{\"id\":\"https://openalex.org/A5137310021\",\"display_name\":\"Brice Ozenne\",\"orcid\":\"https://orcid.org/0000-0001-9694-2956\"},{\"id\":\"https://openalex.org/A5137362526\",\"display_name\":\"Patrick M. Fisher\",\"orcid\":\"https://orcid.org/0000-0002-8115-0611\"},{\"id\":\"https://openalex.org/A5137327025\",\"display_name\":\"Dea S. Stenbæk\",\"orcid\":null},{\"id\":\"https://openalex.org/A5137356637\",\"display_name\":\"Anja S. Petersen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5086179765\",\"display_name\":\"Sophia Armand\",\"orcid\":\"https://orcid.org/0000-0001-6368-3329\"},{\"id\":\"https://openalex.org/A5137369840\",\"display_name\":\"Drummond E-Wen. McCulloch\",\"orcid\":\"https://orcid.org/0000-0001-6360-5224\"},{\"id\":\"https://openalex.org/A5031514106\",\"display_name\":\"Maja Rou Marstrand-Joergensen\",\"orcid\":\"https://orcid.org/0000-0002-2833-7823\"},{\"id\":\"https://openalex.org/A5137359067\",\"display_name\":\"Sara M. Ulv Larsen\",\"orcid\":\"https://orcid.org/0000-0002-9046-2430\"},{\"id\":\"https://openalex.org/A5072267838\",\"display_name\":\"Annette Johansen\",\"orcid\":\"https://orcid.org/0000-0003-0264-2368\"},{\"id\":\"https://openalex.org/A5125212892\",\"display_name\":\"R O B V Jensen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5015895924\",\"display_name\":\"Gitte M. Knudsen\",\"orcid\":\"https://orcid.org/0000-0003-1508-6866\"},{\"id\":\"https://openalex.org/A5113999896\",\"display_name\":\"M.K. Madsen\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811261449380\",\"is_oa\":false}}","topic_tags":"Chronic Pain,Headache / Migraine,Neuroplasticity,Receptor Pharmacology","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7162798090"},{"id":134,"title":"A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder","normalized_title":"a randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive compulsive disorder","authors":"Francisco A. Moreno, Katja Ehrmann Allen, Christopher B. Wiegand, Rajan Dunne, James I. Prickett, Brian Bayze, John J. B. Allen","abstract":"BACKGROUND: Current treatments for obsessive-compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed. AIMS: This randomized clinical trial evaluated safety, tolerability, and benefit of multiple psilocybin doses in OCD patients. METHODS: = 5 per condition), followed by four additional high-dose sessions (single-blind Phase 2). OCD severity was assessed with the Yale-Brown Obsessive Compulsive Scale (YBOCS) following each session, and prospectively for 6 months. Safety was evaluated via adverse event systematic assessment, suicide severity rating, and psychosis screening. RESULTS: Psilocybin was generally well-tolerated, with no serious adverse events, or psychotic symptoms, and no significant changes in suicide severity scores. Psilocybin but not placebo significantly reduced YBOCS scores. At the end of 8-week treatment, after participants had received at least four high doses of psilocybin, 73.3% were responders (⩾35% reduction in YBOCS scores), with 40% in remission. These effects diminished but remained substantial at 6 months. Post hoc analysis of cumulative dosing correlated with YBOCS score reductions at the end of treatment. CONCLUSIONS: Administration of up to eight doses of psilocybin in a clinical research setting appears to be safe and potentially effective for patients with OCD. Larger trials are needed to further support efficacy and refine treatment protocols. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT03300947.","journal":"Journal of Psychopharmacology","publication_date":"2026-03-12","publication_year":2026,"doi":"10.1177/02698811261424214","pubmed_id":"41825921","source_url":"https://doi.org/10.1177/02698811261424214","keywords":"Psilocybin, Randomized controlled trial, Adverse effect, Placebo, Medicine, Psychosis, Clinical trial, Reuptake inhibitor, Fluoxetine, Dosing, Hallucinogen, Psychology, Anesthesia, Psychiatry, Severity of illness, Internal medicine, Rating scale, Anxiety disorder, Obsessive compulsive, Agonist, Post-hoc analysis, Serotonin reuptake inhibitor, Crossover study, Schizophrenia (object-oriented programming), Psychedelics and Drug Studies, Pain Management and Placebo Effect, Forensic Toxicology and Drug Analysis","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-04 07:00:31","raw_json":"{\"openalex_id\":\"https://openalex.org/W7135170485\",\"openalex_url\":\"https://openalex.org/W7135170485\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W122113993\",\"https://openalex.org/W2006001020\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2087854982\",\"https://openalex.org/W2108696783\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2138204170\",\"https://openalex.org/W2141403362\",\"https://openalex.org/W2148083007\",\"https://openalex.org/W2306891185\",\"https://openalex.org/W2792086414\",\"https://openalex.org/W2902990194\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W3027721867\",\"https://openalex.org/W3109908198\",\"https://openalex.org/W3172784626\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W3214305299\",\"https://openalex.org/W4223491164\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4310735641\",\"https://openalex.org/W4385954214\",\"https://openalex.org/W4391286658\",\"https://openalex.org/W4393118291\",\"https://openalex.org/W4393359395\",\"https://openalex.org/W4394566107\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4411969620\",\"https://openalex.org/W7113899315\"],\"authorships\":[{\"id\":null,\"display_name\":\"Francisco A. Moreno\",\"orcid\":\"https://orcid.org/0009-0008-0700-6508\"},{\"id\":\"https://openalex.org/A5104303567\",\"display_name\":\"Katja Ehrmann Allen\",\"orcid\":null},{\"id\":\"https://openalex.org/A5005073454\",\"display_name\":\"Christopher B. Wiegand\",\"orcid\":null},{\"id\":\"https://openalex.org/A5109080350\",\"display_name\":\"Rajan Dunne\",\"orcid\":null},{\"id\":\"https://openalex.org/A5023032729\",\"display_name\":\"James I. Prickett\",\"orcid\":null},{\"id\":\"https://openalex.org/A5129046947\",\"display_name\":\"Brian Bayze\",\"orcid\":null},{\"id\":null,\"display_name\":\"John J. B. Allen\",\"orcid\":\"https://orcid.org/0000-0002-3417-6720\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811261424214\",\"is_oa\":false}}","topic_tags":"Anxiety,OCD,Chronic Pain,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Safety,Adverse Events,Toxicity","study_type":"Randomized Controlled Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7135170485"},{"id":267,"title":"Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature","normalized_title":"effects of lsd dmt and psilocybin on cognitive and psychological functions a systematic review of the literature","authors":"Marten Kase, Kristjan Kaup, Jaan Aru","abstract":"We carried out a systematic review of modern-era (1990-2025) placebo-controlled studies assessing the acute and post-acute effects of lysergic acid diethylamide, dimethyltryptamine and psilocybin on cognitive and psychological functions. From February 28 to March 19, 2025, PubMed and APA PsychINFO were systematically searched for placebo-controlled studies examining the influence of psychedelics on empathy, reaction time, attention, inhibition, emotional processing, memory, cognitive flexibility, and related cognitive functions using experimental methods. Additional searches were done in Google Scholar. The systematic review included 32 studies. Psychedelics tended to enhance emotional empathy but had no effect on cognitive empathy. Psychedelics impaired, enhanced or had no effect on memory depending on the task and timing of the assessment. Dose-dependent impairments were seen in many of the reaction time, attention, and inhibition tasks, although some studies found no effects. Some studies found impaired recognition of negative stimuli under the acute effects of psychedelics. The findings regarding cognitive flexibility were mixed. Many studies had small samples, and it is hard to find a reliable placebo due to psychedelics' unique subjective effects. Future studies should use bigger samples and also study more longitudinal effects of psychedelics on cognitive and psychological functions.","journal":"Journal of Psychopharmacology","publication_date":"2026-02-15","publication_year":2026,"doi":"10.1177/02698811251412012","pubmed_id":"41699449","source_url":"https://doi.org/10.1177/02698811251412012","keywords":"Psilocybin, Cognition, Psychology, Hallucinogen, Empathy, Clinical psychology, Dissociative, Placebo, Flexibility (engineering), Cognitive flexibility, Cognitive psychology, MEDLINE, Psychotherapist, Lysergic acid, Task (project management), Subliminal stimuli, Cognitive neuroscience, Elementary cognitive task, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-04 07:00:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7129773189\",\"openalex_url\":\"https://openalex.org/W7129773189\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1783354124\",\"https://openalex.org/W1857921554\",\"https://openalex.org/W1966592369\",\"https://openalex.org/W1967663070\",\"https://openalex.org/W1974074998\",\"https://openalex.org/W1980563902\",\"https://openalex.org/W1990666634\",\"https://openalex.org/W1993616139\",\"https://openalex.org/W1994271186\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2007442068\",\"https://openalex.org/W2008032124\",\"https://openalex.org/W2008161183\",\"https://openalex.org/W2014885375\",\"https://openalex.org/W2015634454\",\"https://openalex.org/W2018604380\",\"https://openalex.org/W2026493036\",\"https://openalex.org/W2029135043\",\"https://openalex.org/W2030503894\",\"https://openalex.org/W2038005696\",\"https://openalex.org/W2042593075\",\"https://openalex.org/W2047427656\",\"https://openalex.org/W2047691153\",\"https://openalex.org/W2053750947\",\"https://openalex.org/W2063393199\",\"https://openalex.org/W2065759841\",\"https://openalex.org/W2080092700\",\"https://openalex.org/W2082521851\",\"https://openalex.org/W2083198549\",\"https://openalex.org/W2086685463\",\"https://openalex.org/W2088779903\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2112985640\",\"https://openalex.org/W2115308878\",\"https://openalex.org/W2120357670\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2123803218\",\"https://openalex.org/W2130378946\",\"https://openalex.org/W2134831221\",\"https://openalex.org/W2142465953\",\"https://openalex.org/W2145673018\",\"https://openalex.org/W2145998697\",\"https://openalex.org/W2175966792\",\"https://openalex.org/W2181792687\",\"https://openalex.org/W2297557715\",\"https://openalex.org/W2325558246\",\"https://openalex.org/W2413573456\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2443266577\",\"https://openalex.org/W2561419573\",\"https://openalex.org/W2582692487\",\"https://openalex.org/W2589293646\",\"https://openalex.org/W2604586582\",\"https://openalex.org/W2624901555\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2761856500\",\"https://openalex.org/W2793644042\",\"https://openalex.org/W2801092899\",\"https://openalex.org/W2886435130\",\"https://openalex.org/W2928852232\",\"https://openalex.org/W2940999002\",\"https://openalex.org/W2945335566\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2970684805\",\"https://openalex.org/W2972959563\",\"https://openalex.org/W2985843276\",\"https://openalex.org/W2996366481\",\"https://openalex.org/W3010491167\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3027721867\",\"https://openalex.org/W3083216124\",\"https://openalex.org/W3085641834\",\"https://openalex.org/W3093109301\",\"https://openalex.org/W3093676138\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3127399862\",\"https://openalex.org/W3133906491\",\"https://openalex.org/W3144543375\",\"https://openalex.org/W3180562559\",\"https://openalex.org/W3206618060\",\"https://openalex.org/W4200583144\",\"https://openalex.org/W4210511938\",\"https://openalex.org/W4210962567\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4220840388\",\"https://openalex.org/W4226207502\",\"https://openalex.org/W4281386811\",\"https://openalex.org/W4289518537\",\"https://openalex.org/W4294333904\",\"https://openalex.org/W4295449270\",\"https://openalex.org/W4307167512\",\"https://openalex.org/W4309662022\",\"https://openalex.org/W4319079931\",\"https://openalex.org/W4323305766\",\"https://openalex.org/W4361213071\",\"https://openalex.org/W4367319845\",\"https://openalex.org/W4378783751\",\"https://openalex.org/W4381059735\",\"https://openalex.org/W4387674199\",\"https://openalex.org/W4388007338\",\"https://openalex.org/W4388970634\",\"https://openalex.org/W4389854594\",\"https://openalex.org/W4391109410\",\"https://openalex.org/W4392378208\",\"https://openalex.org/W4399390201\",\"https://openalex.org/W4400033755\",\"https://openalex.org/W4400037700\",\"https://openalex.org/W4402655959\",\"https://openalex.org/W4403080353\",\"https://openalex.org/W4403543158\",\"https://openalex.org/W4405510726\",\"https://openalex.org/W4410095934\"],\"authorships\":[{\"id\":\"https://openalex.org/A5126250390\",\"display_name\":\"Marten Kase\",\"orcid\":null},{\"id\":\"https://openalex.org/A5118857368\",\"display_name\":\"Kristjan Kaup\",\"orcid\":\"https://orcid.org/0009-0003-6126-6822\"},{\"id\":\"https://openalex.org/A5087072092\",\"display_name\":\"Jaan Aru\",\"orcid\":\"https://orcid.org/0000-0003-3927-452X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251412012\",\"is_oa\":true}}","topic_tags":"Chronic Pain,Emotional Processing,Systematic Review,Review Article,Toxicity","study_type":"Systematic Review","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7129773189"},{"id":139,"title":"Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience","normalized_title":"effects of psilocybin on personality psychiatric symptoms and values exploring mediating effects of the acute psychedelic experience","authors":"Jess Kerr-Gaffney, Samuel Myrtle, Famia Askari, Catherine Bird, Nadav Liam Modlin, Allan H. Young, James Rucker","abstract":"BACKGROUND: Changes in well-being, personality, and personal values have been documented post-psilocybin; however, evidence from placebo-controlled trials is limited. AIMS: To examine the effects of psilocybin versus placebo on psychiatric symptoms, personality, and personal values in healthy participants. Potential mediators were also explored. METHODS: = 29) in 89 healthy participants. Effects of psilocybin on personality (Neo Five-Factor Inventory; NEO-FFI), psychiatric symptoms (Symptom Checklist-90; SCL-90), and values (Life Changes Inventory; LCI) at short- (day 8) and long-term follow-up (day 85) were analysed using mixed-effects models. Group differences in cognitive flexibility (Intra-Extra Dimensional Set Shift task; IED) at day 8 were analysed using a Kruskal-Wallis test. Potential mediating effects of the acute psychedelic experience (Five-Dimensional Altered States of Consciousness Questionnaire; 5D-ASC) were explored. RESULTS: No between-group differences were found on the NEO-FFI, SCL-90, or IED. Both psilocybin groups showed greater LCI absolute change scores at both follow-up points compared to placebo. The 5D-ASC oceanic boundlessness subscale partially mediated these changes. Oceanic boundlessness also fully or partially mediated differences across several LCI subscales, and auditory alterations mediated differences on one subscale. CONCLUSIONS: The acute psychedelic experience, namely oceanic boundlessness and, to a lesser extent, auditory alterations, mediates self-reported changes in values in healthy volunteers. Findings from this exploratory study are tentative and should be replicated in larger samples.","journal":"Journal of Psychopharmacology","publication_date":"2026-01-25","publication_year":2026,"doi":"10.1177/02698811251408769","pubmed_id":"41588876","source_url":"https://doi.org/10.1177/02698811251408769","keywords":"Psilocybin, Hallucinogen, Psychology, Psychiatry, Exploratory research, Clinical psychology, Medicine, MEDLINE, Lysergic acid diethylamide, Association (psychology), Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-04 07:00:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7125792237\",\"openalex_url\":\"https://openalex.org/W7125792237\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1991682952\",\"https://openalex.org/W2009595390\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2046807857\",\"https://openalex.org/W2081793457\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2135598038\",\"https://openalex.org/W2150781787\",\"https://openalex.org/W2152472333\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2341748123\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2725596576\",\"https://openalex.org/W2756069429\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2784069100\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2957704534\",\"https://openalex.org/W2981695213\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W2999261467\",\"https://openalex.org/W3001118513\",\"https://openalex.org/W3009076589\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3173955184\",\"https://openalex.org/W3185477803\",\"https://openalex.org/W3213458191\",\"https://openalex.org/W4205906672\",\"https://openalex.org/W4220734155\",\"https://openalex.org/W4285091545\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4307838483\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4321377299\",\"https://openalex.org/W4379093876\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4394886406\",\"https://openalex.org/W4395688958\",\"https://openalex.org/W4405528804\"],\"authorships\":[{\"id\":\"https://openalex.org/A5123923706\",\"display_name\":\"Jess Kerr-Gaffney\",\"orcid\":null},{\"id\":\"https://openalex.org/A5124023416\",\"display_name\":\"Samuel Myrtle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123910196\",\"display_name\":\"Famia Askari\",\"orcid\":null},{\"id\":\"https://openalex.org/A5123886072\",\"display_name\":\"Catherine Bird\",\"orcid\":null},{\"id\":\"https://openalex.org/A5037169539\",\"display_name\":\"Nadav Liam Modlin\",\"orcid\":\"https://orcid.org/0000-0002-3900-4354\"},{\"id\":\"https://openalex.org/A5123947312\",\"display_name\":\"Allan H. Young\",\"orcid\":null},{\"id\":\"https://openalex.org/A5124021150\",\"display_name\":\"James Rucker\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251408769\",\"is_oa\":true}}","topic_tags":"Chronic Pain,Consciousness,Wellbeing,Personality Change,Healthy Volunteers","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7125792237"},{"id":350,"title":"An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in mice","normalized_title":"an exploration of the relationships between the effects of psilocybin on behavior 5 ht2a receptor occupancy and neuroplastic effects in mice","authors":"Connor J. Maltby, Adam K. Klein, Enya Paschen, Jessica Pinto, Dino Dvořák, Joseph R. Hedde, Ashley N. Hanks, Massimiliano Bianchi, Zoe Hughes","abstract":"BACKGROUND: Psilocybin has shown rapid and sustained antidepressant effects in patients with major depressive disorder, yet the neurobiological mechanisms underlying these outcomes remain unclear. AIMS: receptor occupancy (RO) achieved after administration of psilocybin and its effects on behavior and markers of neuroplasticity in mice. METHODS: H]MDL-100,907 in the prefrontal cortex (PFC). To relate RO with behavioral outcomes of psilocybin, we assessed the head twitch response (HTR) acutely and investigated behavior in the elevated zero maze (EZM) and forced swim test (FST) 20-24 hours post-drug. Neuroplastic changes were assessed by measuring α-tubulin post-translational modifications (PTMs) and expression of key synaptic proteins in both the PFC and amygdala. RESULTS: RO (RO₅₀ = 0.88 mg/kg) and an inverted-U dose-response in HTR, with peak effects occurring between ~44% and 62% RO. Behaviorally, a 1.5 mg/kg dose increased the open areas ratio in the EZM, while 3 mg/kg reduced immobility in the FST, 20 and 24 hours after dosing, respectively. Both dose levels shifted α-tubulin PTMs toward a more dynamic microtubule state and selectively increased synaptic marker expression in the PFC, not in the amygdala. CONCLUSIONS: These findings suggest that the therapeutic effects of psilocybin could be mediated by dose- and region-specific enhancement of neuronal plasticity, with distinct signatures associated with anxiolytic-like and antidepressant-like properties.","journal":"Journal of Psychopharmacology","publication_date":"2025-12-31","publication_year":2025,"doi":"10.1177/02698811251395386","pubmed_id":"41493065","source_url":"https://doi.org/10.1177/02698811251395386","keywords":"Psilocybin, Neuroplasticity, Neuroscience, Receptor, Hallucinogen, Medicine, Pharmacology, Psychology, Central nervous system, Neural activity, Animal model, Synaptic plasticity, Functional connectivity, Long-term potentiation, Premovement neuronal activity, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Forensic Toxicology and Drug Analysis","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:04","last_checked":"2026-07-04 07:00:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7118979083\",\"openalex_url\":\"https://openalex.org/W7118979083\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1965984522\",\"https://openalex.org/W1969328491\",\"https://openalex.org/W1978714931\",\"https://openalex.org/W1979029926\",\"https://openalex.org/W1981549228\",\"https://openalex.org/W1989982790\",\"https://openalex.org/W1996982933\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W1998939445\",\"https://openalex.org/W2001308670\",\"https://openalex.org/W2005834172\",\"https://openalex.org/W2008172722\",\"https://openalex.org/W2008458074\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2011804248\",\"https://openalex.org/W2017867335\",\"https://openalex.org/W2019163974\",\"https://openalex.org/W2034643906\",\"https://openalex.org/W2037066635\",\"https://openalex.org/W2052466574\",\"https://openalex.org/W2054129965\",\"https://openalex.org/W2064959533\",\"https://openalex.org/W2067481209\",\"https://openalex.org/W2069027411\",\"https://openalex.org/W2074375304\",\"https://openalex.org/W2080084877\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2082303732\",\"https://openalex.org/W2083119103\",\"https://openalex.org/W2086656730\",\"https://openalex.org/W2105815100\",\"https://openalex.org/W2107441654\",\"https://openalex.org/W2129576675\",\"https://openalex.org/W2129662130\",\"https://openalex.org/W2131421588\",\"https://openalex.org/W2135744973\",\"https://openalex.org/W2155768517\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2340978269\",\"https://openalex.org/W2484260316\",\"https://openalex.org/W2519531315\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2583083439\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2761558601\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2793459549\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2808348762\",\"https://openalex.org/W2897545107\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2921683958\",\"https://openalex.org/W2945318261\",\"https://openalex.org/W2999364864\",\"https://openalex.org/W3008629222\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3045334142\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3108222140\",\"https://openalex.org/W3110733646\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3196195007\",\"https://openalex.org/W4200535840\",\"https://openalex.org/W4281254572\",\"https://openalex.org/W4288447327\",\"https://openalex.org/W4293729162\",\"https://openalex.org/W4294967747\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309269582\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4315620747\",\"https://openalex.org/W4362665646\",\"https://openalex.org/W4362722045\",\"https://openalex.org/W4381433809\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386355909\",\"https://openalex.org/W4387893450\",\"https://openalex.org/W4389793820\",\"https://openalex.org/W4390589986\",\"https://openalex.org/W4390691843\",\"https://openalex.org/W4390755783\",\"https://openalex.org/W4391970820\",\"https://openalex.org/W4399458649\",\"https://openalex.org/W4400449392\",\"https://openalex.org/W4404786984\",\"https://openalex.org/W4405695737\",\"https://openalex.org/W4406062303\",\"https://openalex.org/W4406403059\",\"https://openalex.org/W4409310214\"],\"authorships\":[{\"id\":\"https://openalex.org/A5057124222\",\"display_name\":\"Connor J. Maltby\",\"orcid\":\"https://orcid.org/0000-0003-2746-9055\"},{\"id\":\"https://openalex.org/A5022631404\",\"display_name\":\"Adam K. Klein\",\"orcid\":\"https://orcid.org/0000-0002-1640-9324\"},{\"id\":\"https://openalex.org/A5030094587\",\"display_name\":\"Enya Paschen\",\"orcid\":\"https://orcid.org/0000-0001-6323-3889\"},{\"id\":\"https://openalex.org/A5122155101\",\"display_name\":\"Jessica Pinto\",\"orcid\":null},{\"id\":\"https://openalex.org/A5082256940\",\"display_name\":\"Dino Dvořák\",\"orcid\":\"https://orcid.org/0000-0003-3884-1393\"},{\"id\":\"https://openalex.org/A5013053768\",\"display_name\":\"Joseph R. Hedde\",\"orcid\":\"https://orcid.org/0000-0002-6031-754X\"},{\"id\":\"https://openalex.org/A5075277510\",\"display_name\":\"Ashley N. Hanks\",\"orcid\":null},{\"id\":\"https://openalex.org/A5122047740\",\"display_name\":\"Massimiliano Bianchi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101714115\",\"display_name\":\"Zoe Hughes\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251395386\",\"is_oa\":true}}","topic_tags":"Depression,Neuroplasticity,Pharmacology,Mechanism of Action,Receptor Pharmacology,Biomarkers,Animal Study,Toxicity","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7118979083"},{"id":143,"title":"The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures","normalized_title":"the effects of psilocybin on time perception in humans a comparative analysis of subjective and objective measures","authors":"Petr Scholle, Štěpán Wenke, Tereza Nekovářová, Yulia Zaytseva, Filip Tylš, Martin Brunovský, Jiřı́ Horáček, Veronika Andrashko, Vlastimil Koudelka, Michaela Viktorinová, Vojtěch Viktorin, Kateřina Hájková, Martin Kuchař, T. Páleníček","abstract":"Background: Although psychedelics have regained attention as potential treatment tools for various mental disorders, little research has examined their impact on temporal perception. Aims: This double-blinded placebo-controlled study aimed to investigate changes in temporal perception under psilocybin, both through performance during the Temporal Bisection Task (TBT) and through subjective self-report scales. Methods: Twenty-four healthy volunteers were assessed by comparing their performance on two parameters of the TBT -the Bisection Point (BP) and the Just Noticeable Difference (JND) with subjectively reported changes measured using the Hallucinogen Rating Scale (HRS) and the Altered States of Consciousness (ASC) questionnaires. Results: We observed a rightward shift in BP under psilocybin compared to placebo ( t (23) = 2.27, p = 0.033, g = −0.37). This shift corresponded to reports of subjective time slowing down under psilocybin as measured by HRS and ASC. Psilocybin also increased JND compared to placebo ( t (23) = 2.48, p = 0.021, g = −0.47), indicating decreased temporal precision. Consistent with previous findings, these effects were significant for durations longer than 2 seconds. Conclusions: Based on Bayesian framework of timing, we emphasised that psilocybin alters time perception through disruptions in cognitive functions, particularly working memory and attention. We also outlined directions for future research, which would allow us to not only understand time perception under psychedelics better, but help elucidate the role of serotonergic system on timing. Research ID: The research was conducted as part of a clinical trial registered at EudraCT database under the number 2012-004579-37.","journal":"Journal of Psychopharmacology","publication_date":"2025-12-31","publication_year":2025,"doi":"10.1177/02698811251389552","pubmed_id":"41479142","source_url":"https://doi.org/10.1177/02698811251389552","keywords":"Psilocybin, Psychology, Perception, Time perception, Cognition, Cognitive psychology, Working memory, Serotonergic, Anhedonia, Hallucinogen, Developmental psychology, Clinical psychology, Bayesian probability, Expectancy theory, Episodic memory, Visual perception, Automatism (medicine), Cognitive bias, Distress, Psychedelics and Drug Studies, Pain Management and Placebo Effect, Paranormal Experiences and Beliefs","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-04 07:00:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7118000985\",\"openalex_url\":\"https://openalex.org/W7118000985\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1951724000\",\"https://openalex.org/W1996258690\",\"https://openalex.org/W1997058647\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2010322651\",\"https://openalex.org/W2021296709\",\"https://openalex.org/W2023397100\",\"https://openalex.org/W2025964232\",\"https://openalex.org/W2032732419\",\"https://openalex.org/W2042593075\",\"https://openalex.org/W2057409808\",\"https://openalex.org/W2060694206\",\"https://openalex.org/W2065540111\",\"https://openalex.org/W2075814436\",\"https://openalex.org/W2076113015\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2096626991\",\"https://openalex.org/W2109543774\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2139626338\",\"https://openalex.org/W2144455058\",\"https://openalex.org/W2145998697\",\"https://openalex.org/W2164353133\",\"https://openalex.org/W2318447563\",\"https://openalex.org/W2561419573\",\"https://openalex.org/W2802902398\",\"https://openalex.org/W2803735852\",\"https://openalex.org/W2903300049\",\"https://openalex.org/W2905702364\",\"https://openalex.org/W2927301747\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2991098502\",\"https://openalex.org/W2995495462\",\"https://openalex.org/W3042526937\",\"https://openalex.org/W3087190666\",\"https://openalex.org/W4211131282\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4240652873\",\"https://openalex.org/W4241670916\",\"https://openalex.org/W4283160987\",\"https://openalex.org/W4283325106\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4366003487\",\"https://openalex.org/W4385250237\",\"https://openalex.org/W4391451404\",\"https://openalex.org/W4392378208\",\"https://openalex.org/W4406783070\",\"https://openalex.org/W4410022119\",\"https://openalex.org/W4411326423\",\"https://openalex.org/W4412653454\"],\"authorships\":[{\"id\":\"https://openalex.org/A5009629764\",\"display_name\":\"Petr Scholle\",\"orcid\":null},{\"id\":\"https://openalex.org/A5055262118\",\"display_name\":\"Štěpán Wenke\",\"orcid\":\"https://orcid.org/0000-0002-3943-4477\"},{\"id\":\"https://openalex.org/A5003473401\",\"display_name\":\"Tereza Nekovářová\",\"orcid\":\"https://orcid.org/0000-0003-4410-9975\"},{\"id\":\"https://openalex.org/A5121819871\",\"display_name\":\"Yulia Zaytseva\",\"orcid\":null},{\"id\":\"https://openalex.org/A5121823652\",\"display_name\":\"Filip Tylš\",\"orcid\":null},{\"id\":\"https://openalex.org/A5077855950\",\"display_name\":\"Martin Brunovský\",\"orcid\":\"https://orcid.org/0000-0002-2483-0848\"},{\"id\":\"https://openalex.org/A5012893465\",\"display_name\":\"Jiřı́ Horáček\",\"orcid\":\"https://orcid.org/0000-0003-0114-7306\"},{\"id\":\"https://openalex.org/A5029388239\",\"display_name\":\"Veronika Andrashko\",\"orcid\":\"https://orcid.org/0000-0001-5488-3345\"},{\"id\":\"https://openalex.org/A5070851256\",\"display_name\":\"Vlastimil Koudelka\",\"orcid\":\"https://orcid.org/0000-0002-7553-7529\"},{\"id\":\"https://openalex.org/A5121761792\",\"display_name\":\"Michaela Viktorinová\",\"orcid\":null},{\"id\":\"https://openalex.org/A5091098247\",\"display_name\":\"Vojtěch Viktorin\",\"orcid\":\"https://orcid.org/0000-0003-0801-2244\"},{\"id\":\"https://openalex.org/A5000277095\",\"display_name\":\"Kateřina Hájková\",\"orcid\":\"https://orcid.org/0000-0002-5828-2472\"},{\"id\":\"https://openalex.org/A5084865612\",\"display_name\":\"Martin Kuchař\",\"orcid\":\"https://orcid.org/0000-0002-7616-6352\"},{\"id\":\"https://openalex.org/A5013034893\",\"display_name\":\"T. Páleníček\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251389552\",\"is_oa\":false}}","topic_tags":"Chronic Pain,Consciousness,Clinical Trial,Healthy Volunteers","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7118000985"},{"id":149,"title":"High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats","normalized_title":"high dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in sprague dawley rats","authors":"Vítor Bruno, Martha López-Canul, Brandon Richardson, Rosana Camarini, Tânia Marcourakis, Gabriella Gobbi","abstract":"BACKGROUND: In recent years, there has been a resurgence of scientific interest in psychedelics, including psilocybin, for their potential in treating neuropsychiatric disorders. However, the reward-related effects of psilocybin and its impact on behavior remain underexplored. AIMS: We aimed to evaluate the potential rewarding effects of high doses of psilocybin and its effects on rat behavior. METHODS: Sprague-Dawley rats were exposed to the conditioned place preference (CPP) paradigm. Over an 8-day period, rats were administered either psilocybin (10 mg/kg, i.p.) or vehicle (0.9% saline, i.p.) on odd conditioning days, while receiving vehicle (0.9% saline, i.p.) on even conditioning days. The potential rewarding effect induced by psilocybin was assessed 48 hours after the last psilocybin injection. Behavioral assessments, including head twitch, body shaking, grooming, body licking, defecation pellets, and rearing, were conducted during the CPP exposure. RESULTS: Psilocybin did not induce CPP in rats, highlighting its lack of reinforcing effects under these conditions. However, this regimen of administration led to modifications in the behavioral profile during CPP test by increasing head twitching, wet-wet-dog shaking, and defecation pellets and decreasing grooming, body licking, and rearing compared to the vehicle group. Importantly, 48 hours after the final psilocybin injection, no behavioral differences were observed between psilocybin and vehicle groups. CONCLUSION: Psilocybin at this regimen (10 mg/kg, every other day) does not induce CPP, but induces changes in behavior, which disappear 48 hours after the last injection. More research is needed to better evaluate the addiction liability of psychedelics using different paradigms, doses, and protocols.","journal":"Journal of Psychopharmacology","publication_date":"2025-09-21","publication_year":2025,"doi":"10.1177/02698811251368361","pubmed_id":"40984017","source_url":"https://doi.org/10.1177/02698811251368361","keywords":"Psilocybin, Conditioned place preference, Hallucinogen, Anhedonia, Pharmacology, Psychology, Addiction, Preference, Medicine, Neuroscience, Anesthesia, Sensitization, Dopamine, Internal medicine, Amygdala, Endocrinology, Regimen, Anxiety, Schizophrenia (object-oriented programming), Depression (economics), Psychiatry, Hamster, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-04 07:00:33","raw_json":"{\"openalex_id\":\"https://openalex.org/W4414414148\",\"openalex_url\":\"https://openalex.org/W4414414148\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W1268863279\",\"https://openalex.org/W1897852281\",\"https://openalex.org/W1966847383\",\"https://openalex.org/W1973324928\",\"https://openalex.org/W1978960933\",\"https://openalex.org/W1989030177\",\"https://openalex.org/W1992039013\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2006985040\",\"https://openalex.org/W2018806235\",\"https://openalex.org/W2020065445\",\"https://openalex.org/W2021566700\",\"https://openalex.org/W2030687244\",\"https://openalex.org/W2032242574\",\"https://openalex.org/W2039829114\",\"https://openalex.org/W2042469037\",\"https://openalex.org/W2061747140\",\"https://openalex.org/W2063646581\",\"https://openalex.org/W2069822026\",\"https://openalex.org/W2071540027\",\"https://openalex.org/W2074901757\",\"https://openalex.org/W2079258526\",\"https://openalex.org/W2080867289\",\"https://openalex.org/W2092538144\",\"https://openalex.org/W2096717001\",\"https://openalex.org/W2107441654\",\"https://openalex.org/W2142107446\",\"https://openalex.org/W2161047862\",\"https://openalex.org/W2290466312\",\"https://openalex.org/W2298745667\",\"https://openalex.org/W2413330641\",\"https://openalex.org/W2498283353\",\"https://openalex.org/W2551733333\",\"https://openalex.org/W2572835720\",\"https://openalex.org/W2801672416\",\"https://openalex.org/W2809209082\",\"https://openalex.org/W2895529315\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2940358438\",\"https://openalex.org/W2985843276\",\"https://openalex.org/W2987772439\",\"https://openalex.org/W2997108244\",\"https://openalex.org/W2999684597\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3021109112\",\"https://openalex.org/W3027810862\",\"https://openalex.org/W3043557033\",\"https://openalex.org/W3125903050\",\"https://openalex.org/W3134320342\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3162880368\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3196573181\",\"https://openalex.org/W3200052058\",\"https://openalex.org/W3215445661\",\"https://openalex.org/W4200486982\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4220686675\",\"https://openalex.org/W4220730926\",\"https://openalex.org/W4220950644\",\"https://openalex.org/W4224065652\",\"https://openalex.org/W4225295187\",\"https://openalex.org/W4229371915\",\"https://openalex.org/W4239791260\",\"https://openalex.org/W4288447327\",\"https://openalex.org/W4293729162\",\"https://openalex.org/W4308103422\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309269582\",\"https://openalex.org/W4312075150\",\"https://openalex.org/W4315619317\",\"https://openalex.org/W4321088596\",\"https://openalex.org/W4324045013\",\"https://openalex.org/W4362596352\",\"https://openalex.org/W4380225095\",\"https://openalex.org/W4380787361\",\"https://openalex.org/W4384663276\",\"https://openalex.org/W4385479997\",\"https://openalex.org/W4386119120\",\"https://openalex.org/W4387950497\",\"https://openalex.org/W4389793820\",\"https://openalex.org/W4391051065\",\"https://openalex.org/W4394602238\",\"https://openalex.org/W4396640934\",\"https://openalex.org/W4396646618\",\"https://openalex.org/W4400013914\",\"https://openalex.org/W4400174410\",\"https://openalex.org/W4403605401\",\"https://openalex.org/W4403733782\"],\"authorships\":[{\"id\":\"https://openalex.org/A5021635136\",\"display_name\":\"Vítor Bruno\",\"orcid\":\"https://orcid.org/0000-0002-1092-523X\"},{\"id\":\"https://openalex.org/A5068365509\",\"display_name\":\"Martha López-Canul\",\"orcid\":null},{\"id\":\"https://openalex.org/A5052103715\",\"display_name\":\"Brandon Richardson\",\"orcid\":\"https://orcid.org/0000-0002-0325-9216\"},{\"id\":\"https://openalex.org/A5062521491\",\"display_name\":\"Rosana Camarini\",\"orcid\":\"https://orcid.org/0000-0002-8131-6108\"},{\"id\":\"https://openalex.org/A5006008799\",\"display_name\":\"Tânia Marcourakis\",\"orcid\":\"https://orcid.org/0000-0002-0076-5017\"},{\"id\":\"https://openalex.org/A5010580951\",\"display_name\":\"Gabriella Gobbi\",\"orcid\":\"https://orcid.org/0000-0003-4124-9825\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251368361\",\"is_oa\":true}}","topic_tags":"Depression,Anxiety,Addiction,Chronic Pain,Pharmacology,Animal Study,Toxicity","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4414414148"},{"id":361,"title":"Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial","normalized_title":"investigating the safety and tolerability of single dose psilocybin for post traumatic stress disorder a nonrandomized open label clinical trial","authors":"Niall M. McGowan, James Rucker, Rachel Yehuda, Manish Agrawal, Nadav Liam Modlin, Hollie Simmons, Agata Tofil-Kaluza, Shriya Das, Guy M. Goodwin","abstract":"Background: Post-traumatic stress disorder (PTSD) is a debilitating condition for which there are few efficacious treatments. Psilocybin is being studied for use in treatment-resistant depression but has not yet been investigated in PTSD. Aims: The trial’s primary outcome was to investigate the safety and tolerability of single-dose psilocybin in participants with PTSD. Methods: This was a Phase 2, nonrandomized, open-label, multicenter trial. Secondary outcomes were changes in PTSD symptoms (Clinician-Administered PTSD Scale for DSM-5 (CAPS-5); PTSD Checklist for DSM-5 (PCL-5)), functional impairment (Sheehan Disability Scale; SDS) and quality of life (EQ-5D-5L index score). Results: Amongst the 22 participants enrolled (63.6% female; mean (SD) age, 39.0 (7.91) years), there was a total of 117 treatment-emergent adverse events (TEAEs); 70 (59.8%) were reported on administration day, of which 64/70 (91.4%) resolved by the end of the next day. TEAEs commonly included headache ( n = 11; 50.0%), nausea ( n = 8; 36.4%), crying ( n = 6; 27.3%) and fatigue ( n = 6; 27.3%). There were no serious TEAEs or TEAEs leading to study withdrawal. Pre-post comparisons indicated a clinically meaningful change from Baseline in mean CAPS-5 total score at Week 4 (−29.9 (14.06)) and Week 12 (−29.5 (15.43)), which was associated with the intensity of psychedelic experience on Day 1. PCL-5 scores showed symptom reduction was rapid and sustained until Week 12. SDS total score and EQ-5D-5L index score showed similar improvements. Conclusions: Psilocybin at a dose of 25 mg, administered with psychological support, may be safe, well-tolerated and associated with symptomatic improvement in adults with PTSD. Further investigation is warranted. Clinical trial registration: ClinicalTrials.gov Identifier: NCT05312151 (https://clinicaltrials.gov/study/NCT05312151)","journal":"Journal of Psychopharmacology","publication_date":"2025-08-28","publication_year":2025,"doi":"10.1177/02698811251362390","pubmed_id":"40883964","source_url":"https://doi.org/10.1177/02698811251362390","keywords":"Tolerability, Psilocybin, Open label, Traumatic stress, Psychology, Medicine, Clinical trial, Hallucinogen, Anesthesia, Psychiatry, Pharmacology, Adverse effect, Internal medicine, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:04","last_checked":"2026-07-04 07:00:33","raw_json":"{\"openalex_id\":\"https://openalex.org/W4413839750\",\"openalex_url\":\"https://openalex.org/W4413839750\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":10,\"referenced_works\":[\"https://openalex.org/W78677904\",\"https://openalex.org/W1976447964\",\"https://openalex.org/W1979826898\",\"https://openalex.org/W1990166011\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2057489037\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2132981258\",\"https://openalex.org/W2154105276\",\"https://openalex.org/W2473786944\",\"https://openalex.org/W2550807593\",\"https://openalex.org/W2588077070\",\"https://openalex.org/W2592166393\",\"https://openalex.org/W2598895258\",\"https://openalex.org/W2604674575\",\"https://openalex.org/W2612417324\",\"https://openalex.org/W2766807714\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2899448494\",\"https://openalex.org/W2912922214\",\"https://openalex.org/W2912959213\",\"https://openalex.org/W2926998013\",\"https://openalex.org/W2948678705\",\"https://openalex.org/W2950709739\",\"https://openalex.org/W2961809588\",\"https://openalex.org/W2970546318\",\"https://openalex.org/W2991873828\",\"https://openalex.org/W2993548698\",\"https://openalex.org/W2994854287\",\"https://openalex.org/W3008102555\",\"https://openalex.org/W3041627357\",\"https://openalex.org/W3082872736\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3125332567\",\"https://openalex.org/W3127909847\",\"https://openalex.org/W3160990818\",\"https://openalex.org/W3171418018\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3197569079\",\"https://openalex.org/W4205906672\",\"https://openalex.org/W4211189621\",\"https://openalex.org/W4224257950\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4282919933\",\"https://openalex.org/W4292737458\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4383186500\",\"https://openalex.org/W4386740988\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4390628394\",\"https://openalex.org/W4405528804\",\"https://openalex.org/W4405978092\"],\"authorships\":[{\"id\":\"https://openalex.org/A5062136892\",\"display_name\":\"Niall M. McGowan\",\"orcid\":\"https://orcid.org/0000-0001-8183-8558\"},{\"id\":\"https://openalex.org/A5042444567\",\"display_name\":\"James Rucker\",\"orcid\":\"https://orcid.org/0000-0003-4647-8088\"},{\"id\":\"https://openalex.org/A5088026153\",\"display_name\":\"Rachel Yehuda\",\"orcid\":\"https://orcid.org/0000-0001-8307-677X\"},{\"id\":\"https://openalex.org/A5075438055\",\"display_name\":\"Manish Agrawal\",\"orcid\":\"https://orcid.org/0000-0002-0727-6822\"},{\"id\":\"https://openalex.org/A5037169539\",\"display_name\":\"Nadav Liam Modlin\",\"orcid\":\"https://orcid.org/0000-0002-3900-4354\"},{\"id\":\"https://openalex.org/A5030406378\",\"display_name\":\"Hollie Simmons\",\"orcid\":null},{\"id\":\"https://openalex.org/A5119481589\",\"display_name\":\"Agata Tofil-Kaluza\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048446187\",\"display_name\":\"Shriya Das\",\"orcid\":\"https://orcid.org/0000-0002-3988-6326\"},{\"id\":\"https://openalex.org/A5037628078\",\"display_name\":\"Guy M. Goodwin\",\"orcid\":\"https://orcid.org/0000-0002-1426-2816\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251362390\",\"is_oa\":true}}","topic_tags":"Depression,PTSD,Chronic Pain,Headache / Migraine,Pharmacology,Clinical Trial,Treatment-Resistant Depression,Healthcare Workers,Safety,Adverse Events,Toxicity","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4413839750"},{"id":362,"title":"Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics","normalized_title":"pharmacological characterisation of psilocybin and 5 meo dmt discriminative cues in the rat and their translational value for identifying novel psychedelics","authors":"Guy A. Higgins, Cam MacMillan, Inés de Lannoy, Carolyn M. Tyler, Malik Slassi","abstract":"BACKGROUND AND AIMS: Drug discrimination procedures have made important contributions to the pre-clinical investigation of psychedelic drugs, such as psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). One of the most important being to highlight the critical role of central 5-HT2A receptor agonism as a mediator of hallucinogenic activity, and secondly, drugs that fully generalise to a 5-HT2A receptor agonist cued drug discrimination in rodents, may elicit hallucinogenic activity in humans, showing a forward translational value. However, there is relatively little information about how clinical exposures associated with hallucinations back-translate to generalisation profiles in the rat. METHODS: The present series of experiments utilised two cohorts of male Sprague-Dawley rats, one trained to a psilocybin (0.5 mg/kg SC) cue, and the second trained to a 5-MeO-DMT (1 mg/kg SC) cue. RESULTS: Tests of substitution and antagonism supported the primary role of 5-HT2A and 5-HT1A receptors, respectively, in the mediation of each cue. Plasma exposures of psilocin required for generalisation to the psilocybin cue (5-52 ng/mL) overlapped with clinical exposures associated with perceptual effects in humans. With respect to DMT and LSD, higher exposures were required in the rat compared to humans. Time-course studies using an approximate ED90 dose of each psychedelic showed differing temporal profiles in terms of duration of drug-lever generalisation, with LSD > psilocybin > 5-MeO-DMT ⩾ DMT, showing good agreement with clinical experience. With the exception of LSD, there was a good temporal association between plasma exposure and drug lever generalisation. The disconnect noted for LSD is mirrored by similar findings in the clinic. CONCLUSIONS: In summary, the present studies both support and extend the value of the drug discrimination assay as a translational approach to the pre-clinical study of psychedelic drugs.","journal":"Journal of Psychopharmacology","publication_date":"2025-08-26","publication_year":2025,"doi":"10.1177/02698811251361453","pubmed_id":"40862395","source_url":"https://doi.org/10.1177/02698811251361453","keywords":"Psilocybin, Hallucinogen, Psychology, Neuroscience, Value (mathematics), Pharmacology, Medicine, Psychiatry, Computer science, Machine learning, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Neurotransmitter Receptor Influence on Behavior","substance_tags":"psilocybin,psilocin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:04","last_checked":"2026-07-04 07:00:33","raw_json":"{\"openalex_id\":\"https://openalex.org/W4413761559\",\"openalex_url\":\"https://openalex.org/W4413761559\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":1,\"referenced_works\":[\"https://openalex.org/W1727963951\",\"https://openalex.org/W1963690073\",\"https://openalex.org/W1974228627\",\"https://openalex.org/W1975006228\",\"https://openalex.org/W1979676351\",\"https://openalex.org/W1983135802\",\"https://openalex.org/W1986445373\",\"https://openalex.org/W1990245488\",\"https://openalex.org/W1990635352\",\"https://openalex.org/W1998786450\",\"https://openalex.org/W2001116453\",\"https://openalex.org/W2024254226\",\"https://openalex.org/W2034511256\",\"https://openalex.org/W2038393570\",\"https://openalex.org/W2038588928\",\"https://openalex.org/W2040497662\",\"https://openalex.org/W2047050449\",\"https://openalex.org/W2052466574\",\"https://openalex.org/W2055343010\",\"https://openalex.org/W2057298190\",\"https://openalex.org/W2071873589\",\"https://openalex.org/W2075390507\",\"https://openalex.org/W2079106221\",\"https://openalex.org/W2080123927\",\"https://openalex.org/W2082372794\",\"https://openalex.org/W2083916652\",\"https://openalex.org/W2086554492\",\"https://openalex.org/W2090369849\",\"https://openalex.org/W2113573149\",\"https://openalex.org/W2118100568\",\"https://openalex.org/W2121264019\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2126900649\",\"https://openalex.org/W2127165654\",\"https://openalex.org/W2129576675\",\"https://openalex.org/W2170848267\",\"https://openalex.org/W2266545082\",\"https://openalex.org/W2309497242\",\"https://openalex.org/W2318447563\",\"https://openalex.org/W2325885586\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2589071607\",\"https://openalex.org/W2597419566\",\"https://openalex.org/W2600624779\",\"https://openalex.org/W2781316183\",\"https://openalex.org/W2790698047\",\"https://openalex.org/W2794166569\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2951810393\",\"https://openalex.org/W2981860490\",\"https://openalex.org/W2988260994\",\"https://openalex.org/W2999364864\",\"https://openalex.org/W3007555931\",\"https://openalex.org/W3086773311\",\"https://openalex.org/W3091936754\",\"https://openalex.org/W3093375227\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3096897894\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3125697614\",\"https://openalex.org/W3205688202\",\"https://openalex.org/W4206591786\",\"https://openalex.org/W4211131282\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4229446764\",\"https://openalex.org/W4281703399\",\"https://openalex.org/W4295190209\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4311205265\",\"https://openalex.org/W4311564573\",\"https://openalex.org/W4311766514\",\"https://openalex.org/W4323305766\",\"https://openalex.org/W4366742769\",\"https://openalex.org/W4377940122\",\"https://openalex.org/W4378174725\",\"https://openalex.org/W4385196978\",\"https://openalex.org/W4388486766\",\"https://openalex.org/W4389793820\",\"https://openalex.org/W4390754503\",\"https://openalex.org/W4391071347\",\"https://openalex.org/W4391451404\",\"https://openalex.org/W4396732522\",\"https://openalex.org/W4404786984\",\"https://openalex.org/W4405176107\",\"https://openalex.org/W4408608578\",\"https://openalex.org/W4410095934\"],\"authorships\":[{\"id\":\"https://openalex.org/A5027303286\",\"display_name\":\"Guy A. Higgins\",\"orcid\":\"https://orcid.org/0000-0002-0187-8697\"},{\"id\":\"https://openalex.org/A5010506560\",\"display_name\":\"Cam MacMillan\",\"orcid\":null},{\"id\":\"https://openalex.org/A5002854199\",\"display_name\":\"Inés de Lannoy\",\"orcid\":null},{\"id\":\"https://openalex.org/A5066464893\",\"display_name\":\"Carolyn M. Tyler\",\"orcid\":null},{\"id\":\"https://openalex.org/A5058420709\",\"display_name\":\"Malik Slassi\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251361453\",\"is_oa\":true}}","topic_tags":"Pharmacology,Receptor Pharmacology,Observational Study,Animal Study,Toxicity","study_type":"Observational Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4413761559"},{"id":540,"title":"Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression","normalized_title":"examining mystical experiences as a predictor of psilocybin assisted psychotherapy for treatment resistant depression","authors":"Ryan M. Brudner, Erica Kaczmarek, Marc G. Blainey, Christian Schulz, Shakila Meshkat, Zoe Doyle, Orly Lipsitz, Hilary Offman, Rickinder Sethi, Geneva Weiglein, Roger S. McIntyre, Joshua D. Rosenblat","abstract":"BACKGROUND: Psilocybin-assisted psychotherapy (PAP) is a promising treatment for various psychiatric disorders. However, the exact biological and psychological mechanisms of action of PAP remain to be determined. Examining predictors of PAP outcomes may help identify necessary processes for positive treatment outcomes. Mystical experiences are considered a key aspect of the subjective effects of ingesting psilocybin. Mystical experiences have been observed to be possibly predictive of positive outcomes in psilocybin treatments. Therefore, some argue that mystical-type experiences are necessary to achieve therapeutic benefits. AIMS: The current study examines mystical experiences as a predictor of antidepressant treatment outcomes in PAP, in a complex clinical sample. METHODS: Participants included 31 individuals with a primary diagnosis of major depressive disorder (MDD) or Bipolar II Disorder (BDII), with treatment resistance to symptoms of their disorder. Participants had one, two, or three PAP treatments with a fixed dose of 25 mg of psilocybin. Depressive symptoms were measured at baseline, at a pre-dose visit and at 2 weeks post-dosing. The presence of mystical experiences was measured on the dosing day after the acute effects had resolved. RESULTS: For the first psilocybin dose, participants with greater levels of mystical experiences exhibited a greater antidepressant effect from PAP. This effect was not found at the second or third doses. CONCLUSION: These results provide preliminary support for the hypothesis that mystical experiences have therapeutic importance in PAP and extend the literature to include a clinical sample of individuals with treatment-resistant depression in the context of MDD or BDII.","journal":"Journal of Psychopharmacology","publication_date":"2025-06-30","publication_year":2025,"doi":"10.1177/02698811251346697","pubmed_id":"40590216","source_url":"https://doi.org/10.1177/02698811251346697","keywords":"Psilocybin, Context (archaeology), Major depressive disorder, Antidepressant, Psychology, Psychiatry, Mysticism, Psychotherapist, Dosing, Clinical psychology, Depression (economics), Treatment-resistant depression, Medicine, Anxiety, Internal medicine, Cognition, Hallucinogen, Philosophy, Biology, Paleontology, Macroeconomics, Theology, Economics, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:04","last_checked":"2026-07-04 07:00:33","raw_json":"{\"openalex_id\":\"https://openalex.org/W4411880520\",\"openalex_url\":\"https://openalex.org/W4411880520\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":3,\"referenced_works\":[\"https://openalex.org/W62922542\",\"https://openalex.org/W1981740630\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2003424951\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2118739111\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2513336695\",\"https://openalex.org/W2528752100\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2756069429\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2903884088\",\"https://openalex.org/W2911147930\",\"https://openalex.org/W2950747661\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3026821888\",\"https://openalex.org/W3113263685\",\"https://openalex.org/W3134098691\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3213007658\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4240789427\",\"https://openalex.org/W4247582466\",\"https://openalex.org/W4283070601\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4295449270\",\"https://openalex.org/W4318393298\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4362623650\",\"https://openalex.org/W4379093876\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4385230722\",\"https://openalex.org/W4386046484\",\"https://openalex.org/W4386209201\",\"https://openalex.org/W4386686242\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4389397550\",\"https://openalex.org/W4391069738\",\"https://openalex.org/W4391810199\",\"https://openalex.org/W4392550813\",\"https://openalex.org/W4392799954\",\"https://openalex.org/W4399584694\",\"https://openalex.org/W4411392672\",\"https://openalex.org/W6869523170\"],\"authorships\":[{\"id\":\"https://openalex.org/A5093927192\",\"display_name\":\"Ryan M. Brudner\",\"orcid\":\"https://orcid.org/0009-0004-8381-7434\"},{\"id\":\"https://openalex.org/A5104243612\",\"display_name\":\"Erica Kaczmarek\",\"orcid\":null},{\"id\":\"https://openalex.org/A5089394793\",\"display_name\":\"Marc G. Blainey\",\"orcid\":null},{\"id\":\"https://openalex.org/A5101948096\",\"display_name\":\"Christian Schulz\",\"orcid\":\"https://orcid.org/0000-0002-5615-2113\"},{\"id\":\"https://openalex.org/A5037985605\",\"display_name\":\"Shakila Meshkat\",\"orcid\":\"https://orcid.org/0000-0002-7010-1785\"},{\"id\":\"https://openalex.org/A5048402159\",\"display_name\":\"Zoe Doyle\",\"orcid\":\"https://orcid.org/0000-0002-0140-8994\"},{\"id\":\"https://openalex.org/A5091793322\",\"display_name\":\"Orly Lipsitz\",\"orcid\":\"https://orcid.org/0000-0001-9110-7951\"},{\"id\":\"https://openalex.org/A5029059594\",\"display_name\":\"Hilary Offman\",\"orcid\":\"https://orcid.org/0000-0002-6781-2420\"},{\"id\":\"https://openalex.org/A5077689458\",\"display_name\":\"Rickinder Sethi\",\"orcid\":\"https://orcid.org/0000-0003-2356-5859\"},{\"id\":\"https://openalex.org/A5114681119\",\"display_name\":\"Geneva Weiglein\",\"orcid\":null},{\"id\":\"https://openalex.org/A5068850044\",\"display_name\":\"Roger S. McIntyre\",\"orcid\":\"https://orcid.org/0000-0003-4733-2523\"},{\"id\":\"https://openalex.org/A5050740394\",\"display_name\":\"Joshua D. Rosenblat\",\"orcid\":\"https://orcid.org/0000-0002-4773-2191\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251346697\",\"is_oa\":true}}","topic_tags":"Depression,Anxiety,Chronic Pain,Mechanism of Action,Mystical Experience,Treatment-Resistant Depression,Toxicity","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4411880520"},{"id":709,"title":"Psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamus","normalized_title":"psilocybin and ketamine affect novel neuropeptides gene expression in the rat hypothalamus","authors":"Artur Pałasz, Marta Pukowiec, Katarzyna Bogus, Aleksandra Suszka-Świtek, Łukasz Filipczyk, Kinga Mordecka-Chamera, John J. Worthington, Maria Sygidus, Adam Wojtas, Agnieszka Bysiek, Krystyna Gołembiowska","abstract":"OBJECTIVE: Psychedelics are able to trigger highly intense and profound alterations in self-consciousness, perception, affective, and cognitive processes. Indeed, recent studies show that ketamine and psilocybin could be used as fast-acting antidepressants. However, the molecular and neurochemical mechanisms of these psychedelics and their actions at the level of diverse brain structures remains so far unclear. Hypothalamic neuropeptides are involved in a wide spectrum of neuronal activities being responsible for the central control of all fundamental autonomic functions. METHODS: The purpose of this exploratory pilot study was to assess the gene expression of both classical and novel neuropeptides, including nesfatin-1, phoenixin (PNX), spexin (SPX), neuromedin U (NMU), neuropeptide S (NPS), and their known receptors in the hypothalamus of male Wistar-Han rats subjected to single injections of psilocybin (dose 2 or 10 mg/kg) and ketamine (dose10 mg/kg). Total mRNA was isolated from homogenized tissue and real-time PCR was used for estimation of related gene expression. RESULTS: It was found that a single administration of the higher dose of psilocybin increased the mRNA expression of most noncanonical neuropeptides examined in the study, with only the case of NMU there with a decrease in gene expression. Interestingly, psilocybin administration also increased mRNA expression of the serotonin receptors: 5-HT1A, 5-HT2A, and 5-HT2B, but not 5HT-2C. In contrast, the effect of ketamine on the expression of neuropeptides was much more limited compared to psilocybin, only increasing transcripts of NUCB2, GPR173, and POMC were demonstrated. CONCLUSIONS: These results suggest for the first time that selected psychedelics may enhance the signaling of 5-HT2A receptors or inhibit NMDA receptor activity, affecting neuropeptide signaling and serotonin transmission in the rat hypothalamus, which may contribute to a better understanding of psychedelic action in the brain.","journal":"Journal of Psychopharmacology","publication_date":"2025-04-16","publication_year":2025,"doi":"10.1177/02698811251330783","pubmed_id":"40243003","source_url":"https://doi.org/10.1177/02698811251330783","keywords":"Psilocybin, Neuropeptide, Neurochemical, Serotonin, Hypothalamus, Endocrinology, Internal medicine, 5-HT receptor, Receptor, Hallucinogen, Psychology, Neuroscience, Pharmacology, Biology, Medicine, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:04","last_checked":"2026-07-04 07:00:33","raw_json":"{\"openalex_id\":\"https://openalex.org/W4409567941\",\"openalex_url\":\"https://openalex.org/W4409567941\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W70805046\",\"https://openalex.org/W1891846574\",\"https://openalex.org/W1967117235\",\"https://openalex.org/W1980776054\",\"https://openalex.org/W1993254538\",\"https://openalex.org/W1995844603\",\"https://openalex.org/W1995981925\",\"https://openalex.org/W1999914606\",\"https://openalex.org/W2005348933\",\"https://openalex.org/W2010591185\",\"https://openalex.org/W2011885273\",\"https://openalex.org/W2016521818\",\"https://openalex.org/W2017105746\",\"https://openalex.org/W2018420238\",\"https://openalex.org/W2050005079\",\"https://openalex.org/W2052132767\",\"https://openalex.org/W2066433847\",\"https://openalex.org/W2080992988\",\"https://openalex.org/W2094885706\",\"https://openalex.org/W2116939383\",\"https://openalex.org/W2126841876\",\"https://openalex.org/W2128497690\",\"https://openalex.org/W2160415307\",\"https://openalex.org/W2164096103\",\"https://openalex.org/W2167814096\",\"https://openalex.org/W2258423914\",\"https://openalex.org/W2281749991\",\"https://openalex.org/W2299277295\",\"https://openalex.org/W2410812161\",\"https://openalex.org/W2531168951\",\"https://openalex.org/W2746691417\",\"https://openalex.org/W2773111675\",\"https://openalex.org/W2789175114\",\"https://openalex.org/W2793403693\",\"https://openalex.org/W2886998343\",\"https://openalex.org/W2889761695\",\"https://openalex.org/W2909119546\",\"https://openalex.org/W2945318261\",\"https://openalex.org/W2955979325\",\"https://openalex.org/W3008785684\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3110821178\",\"https://openalex.org/W3154588246\",\"https://openalex.org/W3158512805\",\"https://openalex.org/W3184710039\",\"https://openalex.org/W3189488959\",\"https://openalex.org/W3200757480\",\"https://openalex.org/W4210625095\",\"https://openalex.org/W4214937728\",\"https://openalex.org/W4229073012\",\"https://openalex.org/W4281941124\",\"https://openalex.org/W4293729162\",\"https://openalex.org/W4317698893\",\"https://openalex.org/W4320495426\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4378782174\",\"https://openalex.org/W4385197359\",\"https://openalex.org/W4388407376\",\"https://openalex.org/W4388574768\",\"https://openalex.org/W4388641010\",\"https://openalex.org/W4389042154\",\"https://openalex.org/W4389992534\",\"https://openalex.org/W4391451404\",\"https://openalex.org/W4393198452\",\"https://openalex.org/W4394694105\"],\"authorships\":[{\"id\":\"https://openalex.org/A5006211966\",\"display_name\":\"Artur Pałasz\",\"orcid\":\"https://orcid.org/0000-0002-2632-1211\"},{\"id\":\"https://openalex.org/A5114564714\",\"display_name\":\"Marta Pukowiec\",\"orcid\":null},{\"id\":\"https://openalex.org/A5019337660\",\"display_name\":\"Katarzyna Bogus\",\"orcid\":\"https://orcid.org/0000-0001-7476-6445\"},{\"id\":\"https://openalex.org/A5056100362\",\"display_name\":\"Aleksandra Suszka-Świtek\",\"orcid\":\"https://orcid.org/0000-0002-4176-7035\"},{\"id\":\"https://openalex.org/A5089065962\",\"display_name\":\"Łukasz Filipczyk\",\"orcid\":\"https://orcid.org/0000-0001-9352-0715\"},{\"id\":\"https://openalex.org/A5083603747\",\"display_name\":\"Kinga Mordecka-Chamera\",\"orcid\":\"https://orcid.org/0000-0003-1806-7716\"},{\"id\":\"https://openalex.org/A5019050839\",\"display_name\":\"John J. Worthington\",\"orcid\":\"https://orcid.org/0000-0002-1429-5669\"},{\"id\":\"https://openalex.org/A5117202539\",\"display_name\":\"Maria Sygidus\",\"orcid\":null},{\"id\":\"https://openalex.org/A5067587745\",\"display_name\":\"Adam Wojtas\",\"orcid\":\"https://orcid.org/0000-0001-7785-8396\"},{\"id\":\"https://openalex.org/A5022505011\",\"display_name\":\"Agnieszka Bysiek\",\"orcid\":null},{\"id\":\"https://openalex.org/A5053954553\",\"display_name\":\"Krystyna Gołembiowska\",\"orcid\":\"https://orcid.org/0000-0002-5018-1394\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811251330783\",\"is_oa\":false}}","topic_tags":"Chronic Pain,Pharmacology,Mechanism of Action,Receptor Pharmacology,Consciousness,Animal Study","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4409567941"},{"id":371,"title":"Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials","normalized_title":"psilocybin for major depressive disorder an updated systematic review and meta analysis of randomized clinical trials","authors":"Sepehr Aghajanian, Arman Shafiee, Samira Parvizi Omran, Aida Rezaei Nejad, Kyana Jafarabady, Omid Kohandel Gargari, Shahryar Rajai Firouzabadi, Ida Mohammadi, Touran Bahrami Babaheidari, Mahmood Bakhtiyari","abstract":"Background: Due to the unsatisfactory therapeutic effects of current antidepressants, research has been launched into alternative treatment approaches, such as the administration of psychedelics. Psilocybin, a classic hallucinogen, has been shown to exert considerable positive influence on depression symptoms through its serotonergic and glutamatergic effects. This systematic review and meta-analysis aimed to evaluate the effectiveness of psilocybin in treating depression. Methods: A comprehensive search of Medline (via PubMed) and the Cochrane Library databases was conducted to identify relevant studies. Inclusion criteria were applied to select studies that investigated the therapeutic impact of psilocybin on depression. A mixed-effects multi-level model was used to estimate the overall effect size. Effectiveness over time was also investigated as a secondary analysis. Results: The results of the primary analysis revealed a large and clinically observable reduction (SMC: −1.24, 95%CI: −1.83 to −0.65, I2 level2 = 11.39%, I2 level3 = 77.67%) of depressive symptomatology in patients receiving psilocybin in addition to supportive therapy compared to baseline measurements. The decrease was also marked when compared to placebo ( p -value = 0.032). The results remained significant even when a secondary analysis assessed the effect in various time intervals since the administration of psilocybin. Conclusion: This systematic review and meta-analysis substantiate the claim that psilocybin is superior in treating depression compared to established psychotherapy alone used for treating depression. This finding warrants further studies with larger sample sizes and across a longer timeframe.","journal":"Journal of Psychopharmacology","publication_date":"2024-10-30","publication_year":2024,"doi":"10.1177/02698811241287542","pubmed_id":"39480198","source_url":"https://doi.org/10.1177/02698811241287542","keywords":"Psilocybin, Hallucinogen, Meta-analysis, Placebo, Cochrane Library, Randomized controlled trial, Depression (economics), Serotonergic, Medicine, Systematic review, Psychology, MEDLINE, Psychiatry, Clinical psychology, Internal medicine, Alternative medicine, Serotonin, Economics, Law, Political science, Pathology, Macroeconomics, Receptor, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:04","last_checked":"2026-07-04 07:00:34","raw_json":"{\"openalex_id\":\"https://openalex.org/W4403943147\",\"openalex_url\":\"https://openalex.org/W4403943147\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":12,\"referenced_works\":[\"https://openalex.org/W1980910164\",\"https://openalex.org/W2014381681\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2048303608\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2088928458\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2132324173\",\"https://openalex.org/W2139168999\",\"https://openalex.org/W2153403353\",\"https://openalex.org/W2161374186\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2223813100\",\"https://openalex.org/W2273917694\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2992679405\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3001030361\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3083216124\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3201625402\",\"https://openalex.org/W3216485471\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4282931386\",\"https://openalex.org/W4302773366\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4327895864\",\"https://openalex.org/W4366089680\",\"https://openalex.org/W4382360440\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4387516067\"],\"authorships\":[{\"id\":\"https://openalex.org/A5076558683\",\"display_name\":\"Sepehr Aghajanian\",\"orcid\":\"https://orcid.org/0000-0001-6062-0138\"},{\"id\":\"https://openalex.org/A5057425365\",\"display_name\":\"Arman Shafiee\",\"orcid\":\"https://orcid.org/0000-0002-1941-4399\"},{\"id\":\"https://openalex.org/A5108956010\",\"display_name\":\"Samira Parvizi Omran\",\"orcid\":null},{\"id\":\"https://openalex.org/A5056414839\",\"display_name\":\"Aida Rezaei Nejad\",\"orcid\":\"https://orcid.org/0000-0001-7737-7824\"},{\"id\":\"https://openalex.org/A5034353654\",\"display_name\":\"Kyana Jafarabady\",\"orcid\":null},{\"id\":\"https://openalex.org/A5005668391\",\"display_name\":\"Omid Kohandel Gargari\",\"orcid\":\"https://orcid.org/0000-0002-8182-0582\"},{\"id\":\"https://openalex.org/A5093084614\",\"display_name\":\"Shahryar Rajai Firouzabadi\",\"orcid\":\"https://orcid.org/0000-0001-6511-4103\"},{\"id\":\"https://openalex.org/A5010234694\",\"display_name\":\"Ida Mohammadi\",\"orcid\":\"https://orcid.org/0000-0002-0662-0329\"},{\"id\":\"https://openalex.org/A5050431840\",\"display_name\":\"Touran Bahrami Babaheidari\",\"orcid\":\"https://orcid.org/0000-0002-8516-5597\"},{\"id\":\"https://openalex.org/A5060173628\",\"display_name\":\"Mahmood Bakhtiyari\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811241287542\",\"is_oa\":false}}","topic_tags":"Depression,Chronic Pain,Receptor Pharmacology,Clinical Trial,Randomized Controlled Trial,Meta-Analysis,Systematic Review,Review Article,Toxicity","study_type":"Randomized Controlled Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4403943147"},{"id":1005,"title":"Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire","normalized_title":"altered states of consciousness in danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention danish validation of the five dimensional altered states of consciousness questionnaire","authors":"Oliver Rumle Hovmand, M. Madsen, Patrick M. Fisher, Dea Siggaard Stenbæk","abstract":"BACKGROUND: Psychedelic substances reliably induce marked altered states of consciousness (ASC), which may be important for lasting effects and clinical outcomes of psychedelic intervention. Several instruments are available to measure the acute psychedelic experience, of which the Five Dimensional Altered States of Consciousness Questionnaire (5D-ASC) is commonly used. The questionnaire can be scored and analyzed as having five dimensions or 11 subscales, but the two have not been evaluated with comparable factor analysis methods. METHODS: = 550), who reported retrospectively through an online survey based on their most recent experience with psilocybin. We calculated internal consistency measures of Cronbach's alpha and McDonald's omega, conducted a confirmatory factor analysis of the previously suggested factor structures, and tested for possible associations between the 5D-ASC total scores and dose, setting, and intention. For the 11 subscales, we reported omega-sem (composite reliability) using the parameters of the fitted confirmatory factor analyses model. RESULTS: Confirmatory factor analysis showed that the 11 subscales had a good fit to data and showed a better fit compared to the originally proposed five-dimensional solution and good internal consistencies. We further found that the 5D-ASC total scores correlated positively with the dose in the recreative sample. We found no correlations between 5D-ASC total scores and intention or setting. DISCUSSION: We find the Danish 5D-ASC to be a valid tool for measuring ASC among Danish-speaking individuals.","journal":"Journal of Psychopharmacology","publication_date":"2024-08-12","publication_year":2024,"doi":"10.1177/02698811241269669","pubmed_id":"39135498","source_url":"https://doi.org/10.1177/02698811241269669","keywords":"Psilocybin, Danish, Altered state, Consciousness, Psychology, Recreation, Psychiatry, Clinical psychology, Hallucinogen, Medicine, Political science, Neuroscience, Linguistics, Law, Philosophy, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:05","last_checked":"2026-07-04 07:00:35","raw_json":"{\"openalex_id\":\"https://openalex.org/W4401553097\",\"openalex_url\":\"https://openalex.org/W4401553097\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":9,\"referenced_works\":[\"https://openalex.org/W1913957972\",\"https://openalex.org/W2000380427\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2027716222\",\"https://openalex.org/W2038555815\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2071666535\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2100834566\",\"https://openalex.org/W2111742571\",\"https://openalex.org/W2118338381\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2140739497\",\"https://openalex.org/W2161555895\",\"https://openalex.org/W2306810735\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2528752100\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2756069429\",\"https://openalex.org/W2762822955\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2810245683\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W3009076589\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3135335789\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W4211150788\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4294631080\",\"https://openalex.org/W4302007737\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4308372082\",\"https://openalex.org/W4313530670\",\"https://openalex.org/W4383187032\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4388731626\",\"https://openalex.org/W4390915995\",\"https://openalex.org/W4399648513\"],\"authorships\":[{\"id\":\"https://openalex.org/A5087106624\",\"display_name\":\"Oliver Rumle Hovmand\",\"orcid\":\"https://orcid.org/0000-0001-6928-6113\"},{\"id\":\"https://openalex.org/A5000203733\",\"display_name\":\"M. Madsen\",\"orcid\":\"https://orcid.org/0000-0001-8836-1844\"},{\"id\":\"https://openalex.org/A5021085020\",\"display_name\":\"Patrick M. Fisher\",\"orcid\":\"https://orcid.org/0000-0002-8115-0611\"},{\"id\":\"https://openalex.org/A5004791170\",\"display_name\":\"Dea Siggaard Stenbæk\",\"orcid\":\"https://orcid.org/0000-0002-5439-4637\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811241269669\",\"is_oa\":false}}","topic_tags":"Consciousness,Creativity,Observational Study,Healthy Volunteers,Toxicity","study_type":"Observational Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4401553097"},{"id":1061,"title":"Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study","normalized_title":"developing the open psychedelic evaluation nexus consensus measures for assessment of supervised psilocybin services an e delphi study","authors":"P. Todd Korthuis, Kim Hoffman, Adrianne R. Wilson-Poe, Jason B. Luoma, Alissa Bazinet, Kellie Pertl, David L. Morgan, Ryan Cook, Sarann Bielavitz, Renae Myers, R. Cameron Wolf, Dennis McCarty, Christopher S. Stauffer","abstract":"BACKGROUND: Voter initiatives in Oregon and Colorado authorize legal frameworks for supervised psilocybin services, but no measures monitor safety or outcomes. AIMS: To develop core measures of best practices. METHODS: A three-phase e-Delphi process recruited 36 experts with 5 or more years' experience facilitating psilocybin experiences in various contexts (e.g., ceremonial settings, indigenous practices, clinical trials), or other pertinent psilocybin expertise. Phase I, an on-line survey with qualitative, open-ended text responses, generated potential measures to assess processes, outcomes, and structure reflecting high quality psilocybin services. In Phase II, experts used seven-point Likert scales to rate the importance and feasibility of the Phase I measures. Measures were priority ranked. Qualitative interviews and analysis in Phase III refined top-rated measures. RESULTS: = 36; 53% female; 71% white; 56% heterosexual) reported currently providing psilocybin services (64%) for a mean of 15.2 [SD13.1] years, experience with indigenous psychedelic practices (67%), and/or conducting clinical trials (36%). Thematic analysis of Phase I responses yielded 55 candidate process measures (e.g., preparatory hours with client, total dose of psilocybin administered, documentation of touch/sexual boundaries), outcome measures (e.g., adverse events, well-being, anxiety/depression symptoms), and structure measures (e.g., facilitator training in trauma informed care, referral capacity for medical/psychiatric issues). In Phase II and III, experts prioritized a core set of 11 process, 11 outcome, and 17 structure measures that balanced importance and feasibility. CONCLUSION: Service providers and policy makers should consider standardizing core measures developed in this study to monitor the safety, quality, and outcomes of community-based psilocybin services.","journal":"Journal of Psychopharmacology","publication_date":"2024-06-17","publication_year":2024,"doi":"10.1177/02698811241257839","pubmed_id":"38888164","source_url":"https://doi.org/10.1177/02698811241257839","keywords":"Psilocybin, Delphi method, Thematic analysis, Psychology, Applied psychology, Medicine, Qualitative research, Clinical psychology, Psychiatry, Hallucinogen, Computer science, Social science, Artificial intelligence, Sociology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:05","last_checked":"2026-07-04 07:00:35","raw_json":"{\"openalex_id\":\"https://openalex.org/W4399780176\",\"openalex_url\":\"https://openalex.org/W4399780176\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":14,\"referenced_works\":[\"https://openalex.org/W1551186209\",\"https://openalex.org/W1967766053\",\"https://openalex.org/W1979290264\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2045507107\",\"https://openalex.org/W2100069180\",\"https://openalex.org/W2110142496\",\"https://openalex.org/W2122884679\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2726613221\",\"https://openalex.org/W2905110776\",\"https://openalex.org/W2964311550\",\"https://openalex.org/W3124902931\",\"https://openalex.org/W3149986569\",\"https://openalex.org/W3170399214\",\"https://openalex.org/W4250639036\",\"https://openalex.org/W4281666404\",\"https://openalex.org/W4291227674\",\"https://openalex.org/W4296481593\",\"https://openalex.org/W4385265010\"],\"authorships\":[{\"id\":\"https://openalex.org/A5037879583\",\"display_name\":\"P. Todd Korthuis\",\"orcid\":\"https://orcid.org/0000-0001-5556-3597\"},{\"id\":\"https://openalex.org/A5082885757\",\"display_name\":\"Kim Hoffman\",\"orcid\":\"https://orcid.org/0000-0003-3063-7881\"},{\"id\":\"https://openalex.org/A5056650801\",\"display_name\":\"Adrianne R. Wilson-Poe\",\"orcid\":\"https://orcid.org/0000-0002-6304-5295\"},{\"id\":\"https://openalex.org/A5009587541\",\"display_name\":\"Jason B. Luoma\",\"orcid\":\"https://orcid.org/0000-0002-3601-7037\"},{\"id\":\"https://openalex.org/A5042118065\",\"display_name\":\"Alissa Bazinet\",\"orcid\":null},{\"id\":\"https://openalex.org/A5073745691\",\"display_name\":\"Kellie Pertl\",\"orcid\":\"https://orcid.org/0009-0008-0861-3609\"},{\"id\":\"https://openalex.org/A5060032144\",\"display_name\":\"David L. Morgan\",\"orcid\":\"https://orcid.org/0000-0001-6014-7643\"},{\"id\":\"https://openalex.org/A5017059128\",\"display_name\":\"Ryan Cook\",\"orcid\":\"https://orcid.org/0000-0001-8754-995X\"},{\"id\":\"https://openalex.org/A5017040379\",\"display_name\":\"Sarann Bielavitz\",\"orcid\":\"https://orcid.org/0000-0003-2104-6991\"},{\"id\":\"https://openalex.org/A5038473517\",\"display_name\":\"Renae Myers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5058096595\",\"display_name\":\"R. Cameron Wolf\",\"orcid\":\"https://orcid.org/0009-0004-8332-0321\"},{\"id\":\"https://openalex.org/A5060056667\",\"display_name\":\"Dennis McCarty\",\"orcid\":\"https://orcid.org/0000-0001-9014-2894\"},{\"id\":\"https://openalex.org/A5077197149\",\"display_name\":\"Christopher S. Stauffer\",\"orcid\":\"https://orcid.org/0000-0002-0888-095X\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811241257839\",\"is_oa\":false}}","topic_tags":"Depression,Anxiety,Wellbeing,Clinical Trial,Observational Study,Safety,Adverse Events,Toxicity","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4399780176"},{"id":1144,"title":"Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice","normalized_title":"psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant like effects in mice","authors":"Xiangting Zhao, Yingjie Du, Yishan Yao, Wei Dai, Yong-Yu Yin, Guyan Wang, Yunfeng Li, Liming Zhang","abstract":"BACKGROUND: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications require weeks or months to exert their effects. However, the mechanisms underlying this action of psilocybin have not been identified. AIMS: To investigate whether psilocybin has rapid and sustained antidepressant-like effects in mice and investigate whether its potential mechanisms of action are related to promoted neuroplasticity. METHODS: We first examined the antidepressant-like effects of psilocybin in normal mice by the forced swimming test and in chronic corticosterone (CORT)-exposed mice by the sucrose preference test and novelty-suppressed feeding test. Furthermore, to explore the role of neuroplasticity in mediating the antidepressant-like effects of psilocybin, we measured structural neuroplasticity and neuroplasticity-associated protein levels in the prefrontal cortex (PFC) and hippocampus. RESULTS: We observed that a single dose of psilocybin had rapid and sustained antidepressant-like effects in both healthy mice and chronic CORT-exposed mice. Moreover, psilocybin ameliorated chronic CORT exposure-induced inhibition of neuroplasticity in the PFC and hippocampus, including by increasing neuroplasticity (total number of dendritic branches and dendritic spine density), synaptic protein (p-GluA1, PSD95 and synapsin-1) levels, BDNF-mTOR signalling pathway activation (BDNF, TrkB and mTOR levels), and promoting neurogenesis (number of DCX-positive cells). CONCLUSIONS: Our results demonstrate that psilocybin elicits robust, rapid and sustained antidepressant-like effects which is accompanied by the promotion of neuroplasticity in the PFC and hippocampus.","journal":"Journal of Psychopharmacology","publication_date":"2024-04-27","publication_year":2024,"doi":"10.1177/02698811241249436","pubmed_id":"38680011","source_url":"https://doi.org/10.1177/02698811241249436","keywords":"Neuroplasticity, Antidepressant, Psilocybin, Behavioural despair test, Synapsin I, Neuroscience, Psychology, Hippocampus, Prefrontal cortex, Synaptic plasticity, Pharmacology, Medicine, Internal medicine, Hallucinogen, Psychiatry, Chemistry, Receptor, Cognition, Membrane, Synaptic vesicle, Biochemistry, Vesicle, Psychedelics and Drug Studies, Neurotransmitter Receptor Influence on Behavior, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:05","last_checked":"2026-07-04 07:00:35","raw_json":"{\"openalex_id\":\"https://openalex.org/W4396229906\",\"openalex_url\":\"https://openalex.org/W4396229906\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":53,\"referenced_works\":[\"https://openalex.org/W254805310\",\"https://openalex.org/W1962252580\",\"https://openalex.org/W1992784372\",\"https://openalex.org/W1996166611\",\"https://openalex.org/W2045988021\",\"https://openalex.org/W2051271111\",\"https://openalex.org/W2160383565\",\"https://openalex.org/W2291443053\",\"https://openalex.org/W2297945963\",\"https://openalex.org/W2307268137\",\"https://openalex.org/W2346390990\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2768441369\",\"https://openalex.org/W2769155717\",\"https://openalex.org/W2771639970\",\"https://openalex.org/W2781361999\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2810237733\",\"https://openalex.org/W2923276583\",\"https://openalex.org/W2935995671\",\"https://openalex.org/W2985843276\",\"https://openalex.org/W2999478951\",\"https://openalex.org/W3001091588\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3094714065\",\"https://openalex.org/W3113989724\",\"https://openalex.org/W3128522568\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3175771699\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3189196458\",\"https://openalex.org/W3195443470\",\"https://openalex.org/W3203928800\",\"https://openalex.org/W4206759226\",\"https://openalex.org/W4210474529\",\"https://openalex.org/W4211263234\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4236357753\",\"https://openalex.org/W4283171136\",\"https://openalex.org/W4308146113\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4315620747\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4386305913\",\"https://openalex.org/W4389003465\"],\"authorships\":[{\"id\":\"https://openalex.org/A5058242531\",\"display_name\":\"Xiangting Zhao\",\"orcid\":null},{\"id\":\"https://openalex.org/A5102798402\",\"display_name\":\"Yingjie Du\",\"orcid\":\"https://orcid.org/0000-0003-4484-5024\"},{\"id\":\"https://openalex.org/A5043861769\",\"display_name\":\"Yishan Yao\",\"orcid\":\"https://orcid.org/0000-0002-8492-1688\"},{\"id\":\"https://openalex.org/A5038067157\",\"display_name\":\"Wei Dai\",\"orcid\":\"https://orcid.org/0000-0001-8278-0159\"},{\"id\":\"https://openalex.org/A5102648206\",\"display_name\":\"Yong-Yu Yin\",\"orcid\":\"https://orcid.org/0000-0003-3045-5543\"},{\"id\":\"https://openalex.org/A5088725738\",\"display_name\":\"Guyan Wang\",\"orcid\":\"https://orcid.org/0000-0003-3098-5472\"},{\"id\":\"https://openalex.org/A5100326031\",\"display_name\":\"Yunfeng Li\",\"orcid\":\"https://orcid.org/0000-0003-2659-8074\"},{\"id\":\"https://openalex.org/A5101545617\",\"display_name\":\"Liming Zhang\",\"orcid\":\"https://orcid.org/0000-0002-9071-8985\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811241249436\",\"is_oa\":false}}","topic_tags":"Chronic Pain,Neuroplasticity,Neurogenesis,Pharmacology,Mechanism of Action,Receptor Pharmacology,Animal Study","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4396229906"},{"id":1148,"title":"Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression","normalized_title":"effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression","authors":"David Erritzøe, Tommaso Barba, Meg J. Spriggs, Fernando E. Rosas, David Nutt, Robin Carhart-Harris","abstract":"BACKGROUND: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and concerns that there may be a negative interaction on efficacy, participants enrolling in psychedelic trials are usually required to discontinue SNRI/SNRIs prior to enrolling. AIMS: Using data from a recent clinical trial examining the comparative efficacy the psychedelic drug psilocybin (P) combined with approximately 20 h of psychological support to a 6-week (daily) course of the SSRI escitalopram plus matched psychological support for major depressive disorder, we explored the effects of discontinuing SSRI/SNRIs prior to study enrolment on study outcomes. METHODS: Exploratory post hoc analyses using linear mixed effects model were performed to investigate the discontinuation effect on various validated depression symptom severity scales and well-being. The impact of SSRI/SNRIs discontinuation on the acute psychedelic experience was also explored. RESULTS/OUTCOMES: In the psilocybin group, there was a reduced treatment effect on all outcome measures for SSRI/SNRIs discontinuers compared with unmedicated patients at trial entry. However, no effects of discontinuation on measures of the acute psychedelic experience were found. CONCLUSION: Discontinuation of SSRI/SNRIs before psilocybin might diminish response to treatment; however, as we did not test SSRI/SNRI continuation in our trial, we cannot infer such causation. Moreover, the exploratory nature of the analyses makes them hypothesis generating, and not confirmatory. A controlled trial of SSRI/SNRI discontinuation versus continuation prior to psilocybin is urgently required.","journal":"Journal of Psychopharmacology","publication_date":"2024-03-21","publication_year":2024,"doi":"10.1177/02698811241237870","pubmed_id":"38520045","source_url":"https://doi.org/10.1177/02698811241237870","keywords":"Escitalopram, Psilocybin, Discontinuation, Psychology, Paroxetine, Major depressive disorder, Psychiatry, Medicine, Hallucinogen, Antidepressant, Anxiety, Cognition, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:05","last_checked":"2026-07-04 07:00:35","raw_json":"{\"openalex_id\":\"https://openalex.org/W4393118291\",\"openalex_url\":\"https://openalex.org/W4393118291\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":26,\"referenced_works\":[\"https://openalex.org/W202333777\",\"https://openalex.org/W265240844\",\"https://openalex.org/W1575252642\",\"https://openalex.org/W1951724000\",\"https://openalex.org/W1970133878\",\"https://openalex.org/W1977708183\",\"https://openalex.org/W2001284148\",\"https://openalex.org/W2020974659\",\"https://openalex.org/W2023687307\",\"https://openalex.org/W2042510791\",\"https://openalex.org/W2045488830\",\"https://openalex.org/W2055312975\",\"https://openalex.org/W2060307846\",\"https://openalex.org/W2071034105\",\"https://openalex.org/W2078389180\",\"https://openalex.org/W2092475629\",\"https://openalex.org/W2099634048\",\"https://openalex.org/W2114613490\",\"https://openalex.org/W2123552131\",\"https://openalex.org/W2131823335\",\"https://openalex.org/W2155959499\",\"https://openalex.org/W2162510673\",\"https://openalex.org/W2169083980\",\"https://openalex.org/W2170904543\",\"https://openalex.org/W2329873939\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2396675581\",\"https://openalex.org/W2397862430\",\"https://openalex.org/W2408297962\",\"https://openalex.org/W2410085988\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2519531315\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2552814605\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2567636536\",\"https://openalex.org/W2605671917\",\"https://openalex.org/W2639909134\",\"https://openalex.org/W2753654430\",\"https://openalex.org/W2783948250\",\"https://openalex.org/W2788337440\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2804151801\",\"https://openalex.org/W2912654919\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2919124707\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2980350741\",\"https://openalex.org/W3003710034\",\"https://openalex.org/W3009076589\",\"https://openalex.org/W3014341075\",\"https://openalex.org/W3094909023\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3107283988\",\"https://openalex.org/W3112535936\",\"https://openalex.org/W3113263685\",\"https://openalex.org/W3122801192\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3164618783\",\"https://openalex.org/W3182390788\",\"https://openalex.org/W3182695044\",\"https://openalex.org/W3191247672\",\"https://openalex.org/W3197897999\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4206700491\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4221001769\",\"https://openalex.org/W4243810801\",\"https://openalex.org/W4247665917\",\"https://openalex.org/W4292338862\",\"https://openalex.org/W4294808278\",\"https://openalex.org/W4308372082\",\"https://openalex.org/W4313251651\",\"https://openalex.org/W4367053025\",\"https://openalex.org/W4372336620\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4384130479\",\"https://openalex.org/W4390186718\",\"https://openalex.org/W6674913956\"],\"authorships\":[{\"id\":\"https://openalex.org/A5044907549\",\"display_name\":\"David Erritzøe\",\"orcid\":\"https://orcid.org/0000-0002-7022-6211\"},{\"id\":\"https://openalex.org/A5005427567\",\"display_name\":\"Tommaso Barba\",\"orcid\":\"https://orcid.org/0000-0003-2565-4628\"},{\"id\":\"https://openalex.org/A5025030452\",\"display_name\":\"Meg J. Spriggs\",\"orcid\":\"https://orcid.org/0000-0002-7800-1586\"},{\"id\":\"https://openalex.org/A5020498855\",\"display_name\":\"Fernando E. Rosas\",\"orcid\":\"https://orcid.org/0000-0001-7790-6183\"},{\"id\":\"https://openalex.org/A5101507504\",\"display_name\":\"David Nutt\",\"orcid\":\"https://orcid.org/0000-0002-6423-9411\"},{\"id\":\"https://openalex.org/A5072682798\",\"display_name\":\"Robin Carhart-Harris\",\"orcid\":\"https://orcid.org/0000-0002-6062-7150\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811241237870\",\"is_oa\":true}}","topic_tags":"Depression,Anxiety,Chronic Pain,Receptor Pharmacology,Wellbeing,Clinical Trial,Safety,Toxicity,Drug Interactions","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4393118291"},{"id":1290,"title":"The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies","normalized_title":"the revival of the psychedelic experience scale revealing its extended mystical visual and distressing experiential spectrum with lsd and psilocybin studies","authors":"Kurt Stocker, Matthias Hartmann, Laura Ley, A. Becker, Friederike Holze, Matthias E. Liechti","abstract":"BACKGROUND: Research with the Psychedelic Experience Questionnaire/Scale (PES) focuses on questions relating to mystical experience (Mystical Experience Questionnaire (MEQ)). The psychometric potential of the non-MEQ items of the PES remains largely unexplored. AIMS: We investigated whether the PES also yields subscales besides the MEQ30 subscales. METHODS: Data from 239 PES measurements (140 healthy participants) from six studies with moderate to high doses of lysergic acid diethylamide and/or psilocybin were included. New subscales (with items other than MEQ30) were created and validated as follows: (1) theoretical derivation of candidate items; (2) removal of items with rare experiences; (3) exploratory factor analysis; and (4) confirmatory factor analysis. Correlations of subscales within the PES and between the PES and the 5-Dimensional Altered States of Consciousness Scale (5D-ASC) were performed. In addition, a cluster analysis using all items (except rare experiences) was performed. RESULTS: The reliability of the four original factors of the MEQ30 was confirmed and four additional factors for the non-MEQ items were revealed: paradoxicality, connectedness, visual experience, and distressing experience. The first two additional factors were strongly correlated with the MEQ30 mystical subscale. Adding the new subscales to the MEQ30 subscales increased the explained variance with the 5D-ASC. The cluster analysis confirmed our main results and provided additional insights for future psychedelic psychometrics. CONCLUSION: The study yields a new validated 6-factor structure for extended mystical experience (MEQ40: MEQ30 + Paradoxicality + Connectedness) and covers psychedelic experience as a whole more comprehensively than has hitherto been possible within a single questionnaire (PES48). The entire PES (PES100) can also be used for further future psychedelic-psychometric research.","journal":"Journal of Psychopharmacology","publication_date":"2023-10-30","publication_year":2023,"doi":"10.1177/02698811231199112","pubmed_id":"37905369","source_url":"https://doi.org/10.1177/02698811231199112","keywords":"Psilocybin, Psychology, Exploratory factor analysis, Confirmatory factor analysis, Mysticism, Clinical psychology, Experiential avoidance, Psychometrics, Hallucinogen, Psychiatry, Anxiety, Structural equation modeling, Theology, Statistics, Mathematics, Philosophy, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Paranormal Experiences and Beliefs","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:05","last_checked":"2026-07-04 07:00:36","raw_json":"{\"openalex_id\":\"https://openalex.org/W4388034792\",\"openalex_url\":\"https://openalex.org/W4388034792\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":22,\"referenced_works\":[\"https://openalex.org/W62922542\",\"https://openalex.org/W1819467863\",\"https://openalex.org/W1913957972\",\"https://openalex.org/W1968524945\",\"https://openalex.org/W1977775666\",\"https://openalex.org/W2001101493\",\"https://openalex.org/W2009122980\",\"https://openalex.org/W2010322651\",\"https://openalex.org/W2024490100\",\"https://openalex.org/W2036448443\",\"https://openalex.org/W2043448843\",\"https://openalex.org/W2047317044\",\"https://openalex.org/W2048630522\",\"https://openalex.org/W2053764826\",\"https://openalex.org/W2070811300\",\"https://openalex.org/W2071666535\",\"https://openalex.org/W2075238613\",\"https://openalex.org/W2075969679\",\"https://openalex.org/W2080218231\",\"https://openalex.org/W2109639789\",\"https://openalex.org/W2119738402\",\"https://openalex.org/W2121441663\",\"https://openalex.org/W2139156375\",\"https://openalex.org/W2140013897\",\"https://openalex.org/W2143111822\",\"https://openalex.org/W2157703634\",\"https://openalex.org/W2325207359\",\"https://openalex.org/W2340085151\",\"https://openalex.org/W2439685582\",\"https://openalex.org/W2528752100\",\"https://openalex.org/W2549202270\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2600164647\",\"https://openalex.org/W2603506674\",\"https://openalex.org/W2644260506\",\"https://openalex.org/W2733512401\",\"https://openalex.org/W2752450108\",\"https://openalex.org/W2756069429\",\"https://openalex.org/W2792444257\",\"https://openalex.org/W2795656446\",\"https://openalex.org/W2799449427\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2962285119\",\"https://openalex.org/W2983486486\",\"https://openalex.org/W2987203272\",\"https://openalex.org/W3021353408\",\"https://openalex.org/W3026821888\",\"https://openalex.org/W3093375227\",\"https://openalex.org/W3195638705\",\"https://openalex.org/W3213378850\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4221108429\",\"https://openalex.org/W4229920826\",\"https://openalex.org/W4240789427\",\"https://openalex.org/W4290631853\",\"https://openalex.org/W4294631080\",\"https://openalex.org/W4298630180\",\"https://openalex.org/W4308372082\",\"https://openalex.org/W4378174725\"],\"authorships\":[{\"id\":\"https://openalex.org/A5028155514\",\"display_name\":\"Kurt Stocker\",\"orcid\":\"https://orcid.org/0000-0002-6161-7114\"},{\"id\":\"https://openalex.org/A5075003968\",\"display_name\":\"Matthias Hartmann\",\"orcid\":\"https://orcid.org/0000-0003-1132-1339\"},{\"id\":\"https://openalex.org/A5102828957\",\"display_name\":\"Laura Ley\",\"orcid\":\"https://orcid.org/0009-0003-9881-4693\"},{\"id\":\"https://openalex.org/A5012996786\",\"display_name\":\"A. Becker\",\"orcid\":\"https://orcid.org/0000-0001-5308-7945\"},{\"id\":\"https://openalex.org/A5028081191\",\"display_name\":\"Friederike Holze\",\"orcid\":\"https://orcid.org/0000-0003-3143-1519\"},{\"id\":\"https://openalex.org/A5071962736\",\"display_name\":\"Matthias E. Liechti\",\"orcid\":\"https://orcid.org/0000-0002-1765-9659\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811231199112\",\"is_oa\":true}}","topic_tags":"Anxiety,Consciousness,Mystical Experience,Healthy Volunteers,Toxicity","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4388034792"},{"id":1343,"title":"Acute but not long-lasting antidepressant-like effect of psilocybin in differential reinforcement of low-rate 72 schedule in rats","normalized_title":"acute but not long lasting antidepressant like effect of psilocybin in differential reinforcement of low rate 72 schedule in rats","authors":"Natalia Malikowska-Racia, Maciej Koniewski, Joanna Gołębiowska, Piotr Popik","abstract":"BACKGROUND: In clinical studies, psychedelics including psilocybin and D-lysergic acid diethylamide (LSD) demonstrate rapid and persistent antidepressant effects. Since the effective treatment with psychedelics is usually provided with psychotherapy, it is debatable whether their prolonged efficacy can be observed in infrahuman species. Preclinical reports on psychedelics' effects most often address their acute actions, and different tests and models provide inconsistent results. The goal of this study was to examine whether the treatment with psilocybin and/or LSD would demonstrate immediate and/or sustained antidepressant-like effects in the differential reinforcement of low-rate responding (DRL) schedule in rats. In contrast to the antidepressant screening tools, the DRL 72s test is known to detect antidepressants with high predictive validity as it differentiates clinically effective antidepressants from other psychoactive drugs in non-stressed animals. METHODS: Adult male Sprague Dawley rats were injected over three consecutive days with psilocybin (1 mg/kg), LSD (0.08 mg/kg), or saline and then tested in DRL 72s for the following 4 weeks. RESULTS: Treatment with psilocybin but not LSD demonstrated an immediate antidepressant-like effect, manifested as an increased number of reinforced presses and response efficiency. By contrast, neither of the drugs showed a long-term (up to 4 weeks following administration) antidepressant-like effect. CONCLUSIONS: Using DRL 72s schedule of reinforcement, we demonstrated the acute antidepressant-like effect of psilocybin but not of LSD, and failed to detect their persistent antidepressant-like efficacy. The present study suggests that the detection of long-lasting antidepressant-like activity in rats could be challenging and may require entirely novel behavioral methods.","journal":"Journal of Psychopharmacology","publication_date":"2023-10-15","publication_year":2023,"doi":"10.1177/02698811231205692","pubmed_id":"37842884","source_url":"https://doi.org/10.1177/02698811231205692","keywords":"Psilocybin, Antidepressant, Hallucinogen, Differential reinforcement, Pharmacology, Psychology, Medicine, Reinforcement, Psychiatry, Anxiety, Social psychology, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-01 06:48:05","last_checked":"2026-07-04 07:00:36","raw_json":"{\"openalex_id\":\"https://openalex.org/W4387661757\",\"openalex_url\":\"https://openalex.org/W4387661757\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":6,\"referenced_works\":[\"https://openalex.org/W651578575\",\"https://openalex.org/W1942655249\",\"https://openalex.org/W1965146355\",\"https://openalex.org/W1973386992\",\"https://openalex.org/W1988157510\",\"https://openalex.org/W1988986188\",\"https://openalex.org/W1989868487\",\"https://openalex.org/W1990666634\",\"https://openalex.org/W2008525776\",\"https://openalex.org/W2018604380\",\"https://openalex.org/W2027397526\",\"https://openalex.org/W2038022666\",\"https://openalex.org/W2038588928\",\"https://openalex.org/W2040034137\",\"https://openalex.org/W2060474298\",\"https://openalex.org/W2065153248\",\"https://openalex.org/W2075552167\",\"https://openalex.org/W2077895829\",\"https://openalex.org/W2078214674\",\"https://openalex.org/W2078821747\",\"https://openalex.org/W2080691978\",\"https://openalex.org/W2081437421\",\"https://openalex.org/W2082074719\",\"https://openalex.org/W2083958927\",\"https://openalex.org/W2087698327\",\"https://openalex.org/W2090152178\",\"https://openalex.org/W2157384069\",\"https://openalex.org/W2164276826\",\"https://openalex.org/W2217700052\",\"https://openalex.org/W2315263438\",\"https://openalex.org/W2320418677\",\"https://openalex.org/W2490107109\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2600119935\",\"https://openalex.org/W2808301300\",\"https://openalex.org/W2888119399\",\"https://openalex.org/W2942667518\",\"https://openalex.org/W2945318261\",\"https://openalex.org/W2970511278\",\"https://openalex.org/W2980264765\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3014917495\",\"https://openalex.org/W3016993897\",\"https://openalex.org/W3020950088\",\"https://openalex.org/W3081506076\",\"https://openalex.org/W3091037153\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3120778817\",\"https://openalex.org/W3134320342\",\"https://openalex.org/W3155245221\",\"https://openalex.org/W3164636525\",\"https://openalex.org/W3179469168\",\"https://openalex.org/W3189196458\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4213145592\",\"https://openalex.org/W4214937728\",\"https://openalex.org/W4220653200\",\"https://openalex.org/W4283011889\",\"https://openalex.org/W4283211919\",\"https://openalex.org/W4294631080\",\"https://openalex.org/W4310684638\",\"https://openalex.org/W4313585689\",\"https://openalex.org/W4323041020\"],\"authorships\":[{\"id\":\"https://openalex.org/A5087332321\",\"display_name\":\"Natalia Malikowska-Racia\",\"orcid\":\"https://orcid.org/0000-0003-1250-7768\"},{\"id\":\"https://openalex.org/A5012816479\",\"display_name\":\"Maciej Koniewski\",\"orcid\":\"https://orcid.org/0000-0001-9437-2822\"},{\"id\":\"https://openalex.org/A5072655660\",\"display_name\":\"Joanna Gołębiowska\",\"orcid\":\"https://orcid.org/0000-0003-2250-2995\"},{\"id\":\"https://openalex.org/A5020658677\",\"display_name\":\"Piotr Popik\",\"orcid\":\"https://orcid.org/0000-0003-0722-1263\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S136368880\",\"source_display_name\":\"Journal of Psychopharmacology\",\"landing_page_url\":\"https://doi.org/10.1177/02698811231205692\",\"is_oa\":true}}","topic_tags":"Anxiety,Chronic Pain,Pharmacology,Animal Study,Toxicity","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W4387661757"}],"total":71,"page":1,"per_page":20,"pages":4,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"Journal of Psychopharmacology","from":null,"to":null,"sort":"newest","page":1,"per_page":"20"}}